Editing RNA sensors in living cells for perceptual response applications using ADAR

By designing sensor RNA with specific nucleotide sequences complement each other with the target RNA and inducing ADAR editing, the RNA sensing problem in the prior art is solved, and the efficient detection and editing of target RNA is achieved, suitable for identifying and manipulating cells in complex environments. .

CN118974276APending Publication Date: 2024-11-15THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202380032397.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-24
Filing Date
2023-02-24
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing RNA sensing technologies have difficulties in identifying and manipulating RNA, especially when identifying harmful cells or performing experimental operations in complex environments, traditional methods are limited by miRNAs or require carefully designed functional RNA structures, and Cells have complex responses to double-stranded RNA, making it difficult to effectively edit specific RNA.

Method used

By designing sensor RNA containing specific nucleotide sequences, complementing the target RNA and inducing ADAR editing, a method for detecting and expressing proteins of target RNA is realized, using ADAR editing to detect target RNA and expressing output proteins in target cells, providing a Modular live RNA sensing system RADAR.

Benefits of technology

It realizes efficient detection and editing of target RNA, can express specific proteins in target cells, improves the flexibility and accuracy of RNA sensing technology, and is suitable for identifying and operating cells in complex environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974276A_ABST
    Figure CN118974276A_ABST
Patent Text Reader

Abstract

A method for expressing a protein in a target cell, the method comprising combining the target cell with a sensor RNA comprising: (ia) a first nucleotide sequence comprising a sensor nucleotide sequence reverse complementary to the target RNA wherein the sensor nucleotide sequence comprises a stem-loop sequence comprising one or more editable codons, and / or (ib) a first nucleotide sequence comprising a sensor nucleotide sequence reverse complementary to the 3 'UTR of the target RNA, where the sensor nucleotide sequence comprises one or more editable codons, and (ii) a second nucleotide sequence encoding a first cleavage domain, and (iii) a third nucleotide sequence encoding an export protein, where the target RNA is present in the target cell.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Government Rights

[0002] This invention was made with government support under Contract GRFP awarded by the National Science Foundation and Contract EB027723 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application claims priority under 35 U.S.C. §119(e) to the filing date of U.S. Provisional Patent Application Serial No. 63 / 313,423, filed on February 24, 2022, the disclosure of which is incorporated herein by reference.

[0005] Sequence Listing

[0006] A sequence listing is provided herein in the form of a txt file sequence listing XML "STAN-1939WO_SEQ_LIST", which was created on February 24, 2023 and is 13KB in size. The contents of the txt file sequence listing XML are incorporated herein by reference in their entirety. Background Art

[0007] Single-cell transcriptomics is often the de facto method for defining cell types and states, but targeting cells based on their RNA profiles remains challenging. For example, RNA sensing and response systems enable the identification and destruction of harmful cells (e.g. in the context of cancer and autoimmune diseases), or the experimental manipulation of specific cells in complex environments (e.g., the nervous and immune systems). Available RNA sensing technologies are limited to miRNAs or require careful design around functional RNA structures such as ribozymes, guide RNAs, or internal ribosome entry sites. For the latter, another confounding factor is the cell's natural response to double-stranded RNA (dsRNA). Editing of dsRNA by adenosine deaminases (ADARs) acting on RNA can edit specific RNAs.

[0008] Provided herein are methods and kits for detecting target RNA and expressing proteins in target cells using ADAR editing. Summary of the invention

[0009] The present disclosure provides a method for expressing a protein in a target cell, the method comprising combining the target cell with a sensor RNA comprising: (ia) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the target RNA, wherein the sensor nucleotide sequence comprises a stem-loop sequence containing one or more editable codons, or (ib) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the 3'UTR of the target RNA, wherein the sensor nucleotide sequence comprises one or more editable codons, and (ii) a second nucleotide sequence encoding a first cleavage domain, and (iii) a third nucleotide sequence encoding an export protein; wherein the target RNA is present in the target cell.

[0010] The present disclosure provides a method for detecting a target RNA, the method comprising (a) combining the biological sample with a sensor RNA comprising: (i) a first nucleotide sequence encoding a marker protein, (ii) a second nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the 3'UTR of the target RNA, wherein the sensor nucleotide sequence comprises a stop codon, (iii) a third nucleotide sequence encoding a second cleavage domain, and (iv) a fourth nucleotide sequence encoding an export protein; and (b) determining the presence of the export protein in the biological sample.

[0011] The present disclosure also provides a method for detecting a target RNA in a biological sample, the method comprising: (a) combining the biological sample with a sensor RNA comprising: (i) a first nucleotide sequence comprising a stem-loop sequence containing one or more stop codons, (ii) a second nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the target RNA, (iii) a third nucleotide sequence encoding a first cleavage domain, and (iv) a fourth nucleotide sequence encoding an export protein; and (b) determining the presence of the export protein in the biological sample.

[0012] The present disclosure provides a method for detecting a target RNA in a biological sample, the method comprising: (a) combining the biological sample with a sensor RNA comprising: (i) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the target RNA, wherein the sensor nucleotide sequence comprises a start codon, and (ii) a second nucleotide sequence encoding an export protein; and (b) determining the presence of the export protein in the biological sample.

[0013] The present disclosure provides a method for detecting a target RNA in a biological sample, the method comprising: (a) combining the biological sample with a sensor RNA comprising: (i) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the target RNA, wherein the sensor nucleotide sequence comprises an AUA sequence, and (ii) a second nucleotide sequence encoding an export protein; and (b) determining the presence of the export protein in the biological sample.

[0014] Also provided are kits for practicing the subject methods. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] The present invention may be better understood by reading the following detailed description in conjunction with the accompanying drawings. It should be emphasized that, according to convention, the various features in the drawings are not drawn to scale. On the contrary, the dimensions of the various features may be arbitrarily enlarged or reduced for clarity. The accompanying drawings include the following figures.

[0016] Figures 1A-1L . Modular in vivo RNA sensing using ADAR editing. a) Once the input RNA binds the sensor sequence, RADAR expresses the output protein, which triggers ADAR editing of the upstream stop codon. b) Sensor 1 detects transfected trigger (target RNA) 1, but not mismatched trigger 2 in human cells, and is enhanced by ADAR1p150 as determined by flow cytometry. c) RADAR output is tightly coupled to input amount. d) Cre recombinase as an alternative output. The reporter gene is turned on by Cre-mediated inversion, and lower reporter gene amounts correspond to higher activation fold ratios. e) RADAR detects genomically integrated doxycycline-induced triggers. f) RADAR detects subsequences within the native 3'UTR. g) RADAR detects endogenous heat shock-inducible genes or endogenously expressed genes regulated by siRNA knockdown via 3'UTR sensors. h) Sensors can be reduced to 72 bp. i) The “split” design allows detection of smaller core sequences. j) Detection of trigger sequences within CDS. k) RADAR is compatible with 85% of the genome. l) Enhancement of RADAR using engineered ADARs that bind sensor mRNA only through MS2-MCP interaction. Chimeric ADARs do not enhance editing of MS2-free sensors. MS2 can be placed in the 3'UTR of the sensor or close to the dsRNA to form the sensor region. In all figures, unless otherwise stated, we report the average output fluorescence intensity (relative in a given experiment) in cells gated for high transfection efficiency. Each point represents a biological replicate, and the horizontal line represents the mean of the data in each group. Significance was determined by a two-tailed Student's t-test with Bonferroni correction.

[0017] Figure 2A-2E. Unique features and potential applications of RADAR. a) Cell classifier that performs consistently across three replicates. b) OR logic. c) AND logic. d) RADAR distinguishes between dinucleotide and mononucleotide variants. e) RADAR functions in plants. Images are taken from representative plants.

[0018] Figure 3A -3G. a) Overview of flow cytometry gating. b) The ratio between the average output fluorescence under triggered and non-triggered conditions depends on the selected marker gating. The 2D density plot shows the output (EGFP fluorescence, GFP-A) as a function of the transfected marker level (mCherry fluorescence, mCherry-A). The gray band indicates the selected gate, as shown in sub-figure a. The track represents the average of EGFP fluorescence in the small mCherry fluorescence box. The points represent the average in the selected gate. Each replicate is a separate track, but the 2D histogram combines all replicates. The rightmost column covers all replicates. The black line represents the average of the replicate averages, and the width indicates the gate. The average matches the average shown in the main figure 1c. c) Enhancer selection affects the baseline signal, with SFFV giving the lowest baseline signal (EGFP fluorescence in the absence of trigger). Promoter variants were combined with the sensor using overlap extension PCR and transfected as linear fragments. d) Sanger sequencing confirmed ADAR editing. e) RADAR does not function in ADAR-deficient cells unless ADAR is provided. f) The p150 isoform of ADAR1 is the best ADAR to improve the dynamic range of RADAR output. g) ADAR levels modulate sensor output. Purple numbers indicate the fold difference of the triggered case without ADAR, pink numbers indicate the fold difference of the untriggered case without ADAR, and black numbers indicate the fold activation after adding the trigger.

[0019] Figure 4A-4I. a) Inducible triggers show incomplete repression, as EGFP can be detected even in the absence of inducer. Parental (no EGFP) or inducible EGFP-integrated cells were transfected with irrelevant sensors (mTagBFP2 transfection tag, mCherry output) and ADAR1-p150 to measure average EGFP expression. b) Calibration curves for inducible EGFP-integrated cell lines were generated using varying amounts of construct plasmid DNA. Overlaps of orange and blue (two replicates) are shown in gray in the figure. c) Estimated number of average mRNA molecules per cell in inducible EGFP-integrated cells with or without inducer. d) Trigger sequences in the CDS perform worse than the exact same sequence placed in the 3'UTR. e) The 3'UTR sensor has no significant effect on triggered protein expression (EGFP fluorescence). f) The sensor with the CDS sequence has minimal effect on triggered mRNA protein expression (1.14-fold decrease in EGFP fluorescence). g) The updated sensor design has incremental benefits on the percentage of genes with at least one, six, or 51 sensor candidates compared to the 90bp 3'UTR-only sensor. h) Mouse transcriptome analysis using the expanded set of sensor designs. i) The triggering strength of the RADAR sensor for the split trigger is much greater when the split moieties are on the same transcript ("1:2") rather than on separate transcripts ("1,2"), demonstrating that gene fusions can be detected using the split design.

[0020] Figure 5 An exemplary sensor RNA containing an editable start codon is depicted.

[0021] Figure 6 An exemplary sensor RNA comprising an editable unstart (AUA) codon is depicted.

[0022] Figure 7 An exemplary sensor RNA containing a stem-loop with an editable codon is depicted.

[0023] Figure 8 Changes in Ψ% (pseudouridine percentage) in sensor IVT mRNA using either UAG or UGA stop codons in the sensor. Using 100% Ψ greatly reduces fold activation; moderate levels of pseudouridine incorporation are acceptable. Analysis was performed at high transfection marker levels (mCherry, a portion of the sensor mRNA) and for trigger-positive cells (BFP).

[0024] Fig. 9 Sensor performance varies with mCherry (sensor) levels, data from Figure 8 Same dataset.

[0025] Fig.10Average output fluorescence at high sensor levels for all 64 NNN sequences in the trigger relative to the UAG stop codon of the sensor. "-" indicates negative control.

[0026] Fig.11 Fig.10 The data in are presented in different ways, with different positions ("n") shown in each row. Logarithmic mean output fluorescence at high sensor levels for all 64 NNN sequences in the trigger relative to the UAG stop codon of the sensor.

[0027] Fig.12 Fold difference in expression between the two trigger sequences.

[0028] Fig.13 The fraction of NNN-NNN pairs that have an on / off ratio above a given threshold. For example, 249 pairs of NNN(on)-NNN(off) triggers can be distinguished where the "on" state is at least 50 times more likely than the "off" state.

[0029] Fig.14 The fraction of NNN-NNN pairs that have an on / off ratio above a given threshold and differ only in a single nucleotide. For example, 11 pairs of NNN(on)-NNN(off) triggers can be distinguished, where the "on" state is at least 50 times more potent than the "off" state, and the trigger sequences differ only in one position.

[0030] Fig.15 Mismatches near the 5'CCA3' sequence in the trigger RNA do not affect sensor performance. "None" - perfect complementarity; "-" - no input; "-1b" - mismatch immediately 5' to CCA; "+2b" - mismatch after one matching base at 3' to CCA.

[0031] Fig.16 An exemplary ModulADAR mechanism with a UAG stop codon and alternatives with UGA and UAA stop codons.

[0032] Fig.17 ModulADAR efficiently detects mRNA input in highly transfected cells, with a 40-fold increase in mean fluorescence.

[0033] Fig.18 uORF works best with ADAR2 overexpression.

[0034] Fig.19 uORF detection of U6-driven RNA, as well as a positive control (AUG in the uORF was mutated to GUG).

[0035] Fig. 20Improve uORF performance by removing the termination in the output of the uORF framework to generate long uORFs.

[0036] Fig.21 Exemplary uORF design where the input RNA is expressed (producing mRNA) from a normal promoter.

[0037] Fig. 22 Example AUG RADAR Mechanism

[0038] Fig.23 AUG RADAR with typical mRNA input.

[0039] Fig.24 AUA RADAR sensor for U6 expressing RNA with ADAR2 overexpression.

[0040] Fig.25 ModulADAR with editable stem-loops enables dual-input OR gating consisting of a single molecule that can bind two different inputs separately.

[0041] Fig.26 Exemplary sensor RNA designs.

[0042] Fig. 27 Example ModulADAR stem-loop variants are derived from natural ADAR editing sites, where modifications include but are not limited to removing the unedited in-frame stop codon, shortening the stem of the stem-loop, or changing the identity of the editable stop codon and its relative mismatch. From left to right, top to bottom are SEQ ID NOs: 1-8

[0043] Fig.28 Evaluation of exemplary ModulADAR stem-loop variants derived from natural ADAR editing sites.

[0044] Fig.29 Exemplary ModulADAR design for single-molecule OR gating. DETAILED DESCRIPTION

[0045] Before describing exemplary embodiments in greater detail, the following definitions are set forth to illustrate and define the meaning and scope of the terms used in the specification.

[0046] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D ED., John Wiley and Sons, New York (1994) and Hale & Markham, THE HARPER COLLINSDICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide the general meaning of many of the terms used herein to the skilled person. Nevertheless, for clarity and ease of reference, certain terms are defined below.

[0047] Certain ranges of values ​​given herein are preceded by the term "about." The term "about" is used herein to provide literal support for the exact number that follows it, as well as numbers that are close to or approximately the number that follows the term. In determining whether a number is close to or approximately a specifically recited number, the close or approximate unrecited number may be a number that, in the context presented, provides a substantial equivalent to the specifically recited number.

[0048] It must be noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. For example, the term "an RNA sensor" refers to one or more RNA sensors, i.e., a single RNA sensor and a plurality of RNA sensors. It should also be noted that the claims can be drafted to exclude any optional elements. Therefore, this statement is intended to serve as antecedent basis for the use of exclusive terminology such as "solely", "only", etc., in conjunction with the recitation of claim elements, or the use of a "negative" limitation.

[0049] The terms "polynucleotide" and "nucleic acid" are used interchangeably herein and refer to a polymeric form of nucleotides of any length, which may be ribonucleotides or deoxynucleotides. Thus, the term includes, but is not limited to, single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derivatized nucleotide bases. The terms "polynucleotide" and "nucleic acid" should be understood to include single-stranded (e.g., forward or reverse) and double-stranded polynucleotides suitable for use in the embodiments described.

[0050] "Hybridizable" or "complementary" or "substantially complementary" means that a nucleic acid (e.g., RNA, DNA) contains a nucleotide sequence that enables it to non-covalently bind in a sequence-specific, antiparallel manner (i.e., nucleic acid specifically binds to complementary nucleic acid) under appropriate in vitro and / or in vivo temperature and solution ionic strength conditions, i.e., to form Watson-Crick base pairs and / or G / U base pairs, "anneal" or "hybridize" to another nucleic acid. Standard Watson-Crick base pairing includes: adenine / adenosine) (A) pairs with thymidine / thymidine (T), A pairs with uracil / uridine (U), and guanine / guanosine) (G) pairs with cytosine / cytidine (C). Inosine (I) base pairs with cytosine / cytidine. In addition, for hybridization between two RNA molecules (e.g., dsRNA) and hybridization between DNA molecules and RNA molecules (e.g., when a DNA target nucleic acid base pairs with a guide RNA, etc.): G can also pair with U base. For example, in the context of tRNA anticodon base pairing with codons in mRNA, G / U base pairing is responsible in part for the degeneracy (i.e., redundancy) of the genetic code. Thus, in the context of the present disclosure, G (e.g., G of the protein-binding fragment (e.g., dsRNA duplex) of a guide RNA molecule; G of a target nucleic acid (e.g., target DNA or RNA) base-paired with a sensor RNA) is considered complementary to both U and C. For example, when a G / U base pair can be formed at a given nucleotide position of a protein-binding fragment (e.g., dsRNA duplex) of a sensor RNA molecule, the position is not considered non-complementary, but rather complementary.

[0051] Hybridization requires that two nucleic acids contain complementary sequences, although there may be mispairing between the bases. The appropriate conditions for hybridization between the two nucleic acids depend on the length and the degree of complementation of the nucleic acids, and these variables are well known in the art. The greater the degree of complementation between the two nucleotide sequences, the greater the melting temperature (Tm) value of the nucleic acid hybrid with these sequences. Usually, the length of hybridizable nucleic acids is 8 nucleotides or more (for example, 10 nucleotides or more, 12 nucleotides or more, 15 nucleotides or more, 20 nucleotides or more, 22 nucleotides or more, 25 nucleotides or more, or 30 nucleotides or more).

[0052] It should be understood that the sequence of the polynucleotide need not be 100% complementary to the sequence of its target nucleic acid in order to carry out specific hybridization. In addition, the polynucleotide can hybridize on one or more segments so that the middle or adjacent segments do not participate in hybridization events (e.g., loop structures or hairpin structures, "protrusions", etc.). The polynucleotide can include 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, 99.5% or more or 100% sequence complementarity with the target region in the target nucleic acid sequence that it will hybridize. For example, 18 of the 20 nucleotides of the antisense compound are complementary to the target region and therefore the antisense nucleic acid of specific hybridization will represent 90% complementarity. The remaining non-complementary nucleotides can be clustered or interspersed with complementary nucleotides, and need not be adjacent to each other or adjacent to complementary nucleotides. Any convenient method can be used to determine the complementarity percentage between the specific nucleic acid sequence segments in the nucleic acid. Exemplary methods include BLAST programs (Basic Local Alignment Search Tool) and PowerBLAST programs (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656) or use of the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), e.g., using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489).

[0053] The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to a polymeric form of amino acids of any length, which may include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides with modified peptide backbones.

[0054] As used herein, the term "naturally occurring" when applied to nucleic acids, proteins, cells or organisms refers to nucleic acids, proteins, cells or organisms found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (including a virus) that can be isolated from a source in nature and has not been intentionally modified by humans in a laboratory is naturally occurring.

[0055] As used herein, the term "exogenous" when applied to nucleic acids or proteins refers to nucleic acids or proteins that are not normally or naturally present in and / or produced by a given bacterium, organism or cell in nature. As used herein, the term "endogenous nucleic acid" refers to nucleic acids that are normally present in and / or produced by a given bacterium, organism or cell in nature. "Endogenous nucleic acid" is also referred to as "natural nucleic acid" or a nucleic acid that is "native" to a given bacterium, organism or cell. As used herein, the term "endogenous polypeptide" refers to a polypeptide that is normally present in and / or produced by a given bacterium, organism or cell in nature.

[0056] "Recombination" as used herein means that a particular nucleic acid or protein is the product of various combinations of cloning, restriction and / or ligation steps, and the construct produced has a structural coding or non-coding sequence that is distinguished from the endogenous nucleic acids found in the natural system. Typically, the DNA sequence encoding the structural coding sequence can be assembled from cDNA fragments and short oligonucleotide linkers or a series of synthetic oligonucleotides to provide a synthetic nucleic acid that can be expressed from a recombinant transcription unit in a cell or cell-free transcription and translation system. Such sequences can be provided in the form of an open reading frame that is not interrupted by internal non-translated sequences or introns that are usually present in eukaryotic genes. Genomic DNA containing related sequences can also be used to form recombinant genes or transcription units. Non-translated DNA sequences may be present at 5' or 3' of the open reading frame, and such sequences do not interfere with the operation or expression of the coding region, and can actually regulate the production of the desired product by various mechanisms.

[0057] Thus, for example, the term "recombinant" nucleic acid or "recombinant" protein refers to a non-naturally occurring nucleic acid or protein, for example, it is formed by artificially combining two originally separated sequence fragments through human intervention. This artificial combination is usually achieved by chemical synthesis methods or artificially operating separated nucleic acid fragments (for example, by genetic engineering techniques). This is usually to replace codons with redundant codons encoding the same or conservative amino acids, and sequence recognition sites are usually introduced or removed. Alternatively, it is performed to join nucleic acid fragments with desired functions together to produce desired functional combinations. This artificial combination is usually achieved by chemical synthesis methods or artificially operating separated nucleic acid fragments (for example, by genetic engineering techniques).

[0058] "Construct" or "vector" refers to a recombinant nucleic acid, typically recombinant DNA, that is produced for the purpose of expressing and / or propagating a nucleotide sequence of interest or for use in constructing other recombinant nucleotide sequences.

[0059] The term "conversion" or "transfection" refers to permanent or transient genetic changes induced in cells after the introduction of nucleic acid (i.e., DNA and / or RNA of exogenous cell). Genetic changes ("modification") can be achieved by integrating new DNA into the genome of the host cell, or by temporarily or stably maintaining the new DNA as an additional element. When the cell is a eukaryotic cell, permanent genetic changes are usually achieved by introducing DNA into the genome of the cell. Suitable methods for genetic modification include viral infection, transfection, conjugation, protoplast fusion, electroporation, particle gun technology, calcium phosphate precipitation, direct microinjection, etc. The selection of the method generally depends on the environment (i.e., in vitro, in vitro or in vivo) in which the cell type and the transformation occur. A general discussion of these methods can be found in Ausubel et al., Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons, 1995.

[0060] The terms "regulatory region" and "regulatory element" are used interchangeably herein and refer to transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, protein degradation signals, translation initiation and termination codons, translation start sites, splicing enhancers / donor / branch / acceptor sites, etc., which provide and / or regulate the expression of a coding sequence and / or the production of a polypeptide encoded in a host cell. As used herein, a "promoter sequence" or "promoter" is a DNA regulatory region that is capable of binding / recruiting RNA polymerase (e.g., via a transcription initiation complex) and initiating transcription of a downstream (3' direction) sequence (e.g., a protein coding ("coding") or non-protein coding ("non-coding") sequence). A promoter can be a constitutively active promoter (e.g., a promoter that is constitutively in an active / "ON" state), can be an inducible promoter (e.g., a promoter whose activity / "ON" or inactive / "OFF" state is controlled by an external stimulus (e.g., the presence of a specific temperature, compound, or protein)), can be a spatially restricted promoter (e.g., a tissue-specific promoter, a cell type-specific promoter, etc.), and / or can be a temporally restricted promoter (e.g., a promoter that is in an "ON" state or an "OFF" state at a specific stage of embryonic development or at a specific stage of a biological process, e.g., the follicle cycle in a hairy mouse).

[0061] "Operably linked" refers to a juxtaposition wherein the described components are in a relationship permitting them to function in their intended manner. For example, a promoter is operably linked to a nucleotide sequence (e.g., a protein coding sequence, e.g., a sequence encoding an mRNA; a non-protein coding sequence, e.g., a sequence encoding a Shh protein; etc.) if the promoter affects its transcription and / or expression.

[0062] The term "adenosine deaminase acting on RNA" or "ADAR" refers to an enzyme that catalyzes the hydrolytic C6 deamination of adenosine (A) to produce inosine (I) in a double-stranded RNA substrate. ADARs preferentially edit double-stranded RNA at mismatch sites, with mismatches containing adenosine and cytosine being edited more efficiently than other mismatches. ADAR editing results in nucleotide substitutions in RNA because purine I generated by the deamination reaction is recognized as G rather than A by the ribosome during mRNA translation decoding and by RNA-dependent polymerases during RNA replication. The term "ADAR" encompasses any known type of ADAR, such as ADAR1 (ADAR) or ADAR2 (ADARB2).

[0063] "ADAR1" as used herein refers to an adenosine deaminase that catalyzes the hydrolysis C6 deamination of adenosine (A) to produce inosine (I) in a double-stranded RNA substrate and acts on RNA. ADAR1 has 2 major isoforms, p150 and p110. The term "ADAR1" encompasses ADAR1 from various species. The amino acid sequences of ADAR1 from various species are publicly available. See, for example, GenBank accession numbers NP_001102 (homo sapiens ADAR1 p150), NP_001180424.1 (homo sapiens ADAR1 p110), NP_001139768 (rat ADAR1 p150), NP_001033676 (rat ADAR1 p110). The term "ADAR1" as used herein also includes fragments, fusion proteins and variants (e.g., variants with one or more amino acid substitutions, additions, deletions and / or insertions) that retain ADAR1 enzymatic activity.

[0064] "ADAR2" as used herein refers to an adenosine deaminase that catalyzes the hydrolysis C6 deamination of adenosine (A) to produce inosine (I) in a double-stranded RNA substrate and acts on RNA. ADAR2 is only localized in the nucleus. The term "ADAR2" encompasses ADAR2 from various species. The amino acid sequences of ADAR2 from various species are publicly available. See, for example, GenBank accession numbers NP_056648.1 (homo sapiens ADAR2), NP_001020008.1 (mouse ADAR2), ACO52474.1 (Doryteuthis opalescens ADAR2). The term "ADAR2" as used herein also includes fragments, fusion proteins and variants (e.g., variants with one or more amino acid substitutions, additions, deletions and / or insertions) that retain ADAR2 enzymatic activity.

[0065] The term "sample" as used herein refers to a material or a mixture of materials, usually (but not necessarily) a fluid, i.e., an aqueous form, containing one or more components of interest. The sample can come from a variety of sources, such as food, environmental materials, biological samples, or solids, such as tissues or fluids separated from individuals, including but not limited to, for example, plasma, serum, spinal fluid, semen, lymph, skin, external sections of the respiratory tract, intestinal tract, and urogenital tract, tears, saliva, milk, blood cells, tumors, organs, and samples of in vitro cell culture components (including but not limited to conditioned medium produced by cell growth in cell culture medium, assumed virus-infected cells, recombinant cells, and cell components). In certain embodiments of the method, the sample includes cells. In some embodiments of the method, the cells are in vitro. In some examples of the method, the cells are in vivo.

[0066] The term "biological sample" encompasses clinical samples or non-clinical samples, and also includes tissues obtained by surgical resection, tissues obtained by biopsy, cells in culture, cell supernatants, cell lysates, tissue samples, organs, bone marrow, blood, plasma, serum, etc. "Biological sample" includes samples obtained from the patient's sample cells, for example, samples containing polynucleotides and / or polypeptides obtained from the patient's sample cells (e.g., cell lysates or other cell extracts containing polynucleotides and / or polypeptides); and samples containing sample cells from the patient. Biological samples containing sample cells from the patient may also include normal, non-diseased cells. Biological samples may be from plants or animals. Biological samples may also be from any species. In certain embodiments of the method, the biological sample includes cells. In some cases of the method, the cells are in vitro. In some cases of the method, the cells are in vivo.

[0067] The term "editable codon" used herein refers to a 3-nucleotide sequence that can be edited by an ADAR protein or a derivative thereof. The codon can be a start codon, a stop codon, or an AUA codon. The codon comprises a sequence containing an adenosine base. Generally speaking, in the methods disclosed herein, an editable codon is a start codon edited as a non-start codon, a stop codon edited as a non-stop codon, or a non-start codon (i.e., AUA) edited as a start codon.

[0068] Detailed Description

[0069] Before describing various embodiments, it should be understood that the teachings of the present disclosure are not limited to the specific embodiments described, and therefore may of course vary. It should also be understood that the terminology used herein is only used to describe specific embodiments and is not intended to be limiting, as the scope of the present teachings is limited only by the appended claims.

[0070] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter in any way. Although the present teachings are described in conjunction with various embodiments, the present teachings are not limited to these embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those skilled in the art.

[0071] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present teachings, some exemplary methods and materials are now described.

[0072] The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present claims are not entitled to antedate such publication by virtue of prior invention. Furthermore, the dates of publication provided may be different from the actual publication dates which can be independently confirmed.

[0073] It will be clear to those skilled in the art after reading this disclosure that each individual embodiment described and illustrated herein has discrete components and features that can be easily separated or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present teachings. Any recited method can be performed in the order of events recited or in any other order that is logically possible.

[0074] All patents and publications cited herein, including all sequences disclosed within such patents and publications, are expressly incorporated by reference.

[0075] Where a numerical range is provided, it is understood that each intermediate value between the upper and lower limits of the range (unless the context clearly indicates otherwise, up to one tenth of the unit of the lower limit) and any other stated or intermediate value in the stated range are encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included in the smaller range and are also encompassed within the present invention, but are subject to the impact of any specifically excluded limitations in the stated range. When the stated range includes one or two limits, ranges excluding one or both of the included limits are also encompassed within the present invention.

[0076] It will be appreciated that certain features of the invention described in separate embodiments for clarity may also be provided in combination in a single embodiment. Conversely, various features of the invention described in individual embodiments for brevity may also be provided individually or in any suitable subcombination. All combinations of embodiments related to the invention are expressly contemplated by the present invention and are disclosed herein as if each combination were individually and expressly disclosed. In addition, all subcombinations of the various embodiments and elements thereof are expressly contemplated by the present invention and are disclosed herein as if each such subcombination were individually and expressly disclosed.

[0077] In further describing the present invention, methods for detecting target RNA are first described in more detail. Next, methods for expressing a target protein of interest are described. Kits are also described.

[0078] Methods for detecting target RNA

[0079] As described above, a method for detecting a target RNA in a biological sample is provided, the method comprising (a) combining the biological sample with a sensor RNA, and (b) determining the presence of an exported protein associated with the detection of the target RNA. In some embodiments, the biological sample is a cell.

[0080] Target RNA can be any RNA.For example, target RNA includes but is not limited to mRNA, long non-coding RNA, transfer RNA, ribosomal RNA, small RNA (such as microRNA), small interfering RNA, small nucleolar RNA, etc. In some embodiments, target RNA can be differentially expressed in different tissue cell types or cell states, and the detection of target RNA can be used to identify tissue type, cell type or cell state. In some embodiments, target RNA can be the genetic variation of gene. In these cases, genetic variation can predict disease or susceptible disease, such as carcinogenic mutation or genetic variation associated with increased susceptibility to pathogens. In some embodiments, the method of the present disclosure can be used to detect point mutations associated with the development of diseases (such as cancer, neurodegenerative diseases, autoimmune diseases, etc.). In some embodiments, the method of the present disclosure can detect small insertions / deletions, single nucleotide polymorphisms (SNPs) or variants, polynucleotide variants or dinucleotide variants, etc. In some embodiments, the method of the present disclosure can detect and distinguish copy number variants in and between biological samples. Target RNA can also be gene fusion, which can predict general cancer or specific types of cancer. Target RNA can also be a specific splicing variant (isomer) of a gene.

[0081] In some embodiments, the sensor RNA includes the following: (i) a first nucleotide sequence encoding a marker protein, (ii) a second nucleotide sequence encoding a first cleavage domain, (iii) a third nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the target RNA, wherein the sensor nucleotide sequence comprises one or more stop codons, (iv) a fourth nucleotide sequence encoding a second cleavage domain, and (v) a fifth nucleotide sequence encoding an export protein.

[0082] In some embodiments, the sensor RNA includes the following: (i) a first nucleotide sequence encoding a marker protein, (ii) a second nucleotide sequence encoding a cleavage domain, (iii) a third nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the 3'UTR of the target RNA, wherein the sensor nucleotide sequence comprises one or more stop codons, (iv) a fourth nucleotide sequence encoding a second cleavage domain, and (v) a fifth nucleotide sequence encoding an export protein.

[0083] In some embodiments, the sensor RNA includes the following: (i) a first nucleotide sequence comprising a stem-loop sequence containing one or more stop codons, (ii) a second nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the target RNA, (iii) a third nucleotide sequence encoding a cleavage domain, and (iv) a fourth nucleotide sequence encoding an export protein.

[0084] In some embodiments, the sensor RNA includes the following: (i) a first nucleotide sequence containing a sensor nucleotide sequence that is reverse complementary to a target RNA, wherein the sensor nucleotide sequence comprises a stem-loop sequence containing one or more stop codons, (ii) a second nucleotide sequence encoding a cleavage domain, and (iii) a third nucleotide sequence encoding an export protein.

[0085] In some embodiments, the sensor RNA includes the following: (i) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to a target RNA, (ii) a second nucleotide sequence comprising a stem-loop sequence containing one or more stop codons, (iii) a third nucleotide sequence encoding a cleavage domain, and (iv) a fourth nucleotide sequence encoding an export protein.

[0086] In some embodiments, the sensor RNA has one or more stop codons, and the stop codon contains at least 1 base, which mismatches with 1) the sequence in the stem loop relative to the stop codon or 2) the sequence in the target RNA. At least 1 mismatched base usually does not exceed 2 mismatched bases. In one embodiment, the sensor RNA has one or more stop codons, and the stop codon contains only 1 base, which mismatches with 1) the sequence in the stem loop relative to the stop codon or 2) the sequence in the target RNA. In some embodiments, the sensor RNA does not have any mismatched bases.

[0087] In certain embodiments, the sensor RNA comprises the first nucleotide sequence to the third, fourth or fifth nucleotide sequence in order (i.e., the fifth nucleotide sequence is located after the fourth nucleotide sequence, the fourth nucleotide sequence is located after the third nucleotide sequence, the third nucleotide sequence is located after the second nucleotide sequence, and the second nucleotide sequence is located after the first nucleotide sequence). In some embodiments, the sensor RNA comprises the first nucleotide sequence to the third, fourth or fifth nucleotide sequence not in the above order.

[0088] The sensor RNA of the present disclosure comprises a sensor nucleotide sequence or a stem-loop sequence comprising one or more stop codons, which is followed by a nucleotide sequence encoding an output protein. In some embodiments, the sensor RNA comprises one or more stop codons, and the stop codon comprises at least one base mismatched with a target RNA or a sequence within the stem-loop. In some embodiments, the sensor RNA does not comprise any mismatch with the target RNA. In the presence of the target RNA, the sensor nucleotide sequence of the sensor RNA hybridizes with the target RNA to form a double-stranded RNA molecule that can recruit ADAR proteins. The double-stranded RNA may comprise a stop codon with or without a mismatch, or the stop codon may be located within the stem-loop of the sensor RNA. Then, the ADAR protein edits the adenosine base within the stop codon of the sensor RNA to an inosine base. This editing deletes the stop codon, thereby allowing the output protein to be produced from the sensor RNA in the biological sample.

[0089] When the sensor RNA contains a nucleotide sequence comprising a stem-loop sequence (which comprises a stop codon), any stem-loop sequence can be used. In some embodiments, the stem-loop comprises a natural editing site. The natural editing site is a natural editing site within the nucleotide sequence. Natural editing sites are known in the art and have been described in, for example, Gabay et al. (Nat Commun. 2022 Mar 4; 13 (1): 1184), which is specifically incorporated herein by reference. Examples of natural editing sites include, but are not limited to, editing sites found in GRIA2, GRIA3, IGFBP7, NEIL1, FLNA, GRIK2, CDK13, GABRA3, GLI1, SPEG, HTR2C, GRIA4, CYFIP2, CADPS, CADPS, RICTOR, COG3, GRIK1, COPA, HBE1, SON, FLNB, MAGEL2, NOVA1, PNMT, WASH1, LAT, DACT3, FXYD5, ZNF717, ZNF551CAPS1, etc. The natural editing sites are also disclosed in Table 1 below. In some embodiments, the stem-loop sequence is a GluR-B stem-loop or a modified variant thereof. In some embodiments, the stem comprises a natural editing site and the loop is a synthetic sequence. In some embodiments, the sequence of the stem is altered by adding or removing nucleotides to add or remove mismatches compared to the natural editing site. In some embodiments, the sequence alteration adds or removes an additional stop codon. In some embodiments, the stem-loop sequence contains a CAPS1 derived stem-loop as follows:

[0090] CAAGGUCAAUGAGGAGAUGUACAUAGAAAUACAAUCCUGUGUACAUCUUCUAGCAUGACCCAC (SEQ ID NO: 1; CAPS1 variant 2). In some embodiments, the stem-loop sequence contains the following CAPS1 derived stem-loop:

[0091] CAAGGUCAAUGAGGAGAUGUACAUAAUACAAUGUGUACAUCUUCUAGCAUGACCCAC (SEQ ID NO: 2; CAPS1 variant 3). In some embodiments, the stem-loop sequence contains the following GLI1-derived stem-loop:

[0092] CCCAACCUCUGUCUACUCACCACAGCCCCCCAGCAUCACUGUGAAUGCUGCCAUGGAUGCUAGAGGGCUACAGGAAGAGCCAGAAGUUGG (SEQ ID NO: 3; GLI1 variant 4). In some embodiments, the stem-loop sequence contains the following GLI1 derived stem-loop: CUCACCACAGCCCCCCAGCAUCACUGUGAAUGCUGCCAUGGAUGCUAGAGGGCUACAGGA (SEQ ID NO: 4; GLI1 variant 5). In some embodiments, the stem-loop sequence contains the following GABRA3 derived stem-loop:

[0093] AAGUGGCAUAUGCGACGGCCAUGGACUGGUUCAUAGCCGUCUGUUAUGCCU (SEQ ID NO: 5; GABRA3 variant 6). In some embodiments, the stem-loop sequence contains the following GABRA3-derived stem-loop:

[0094] UGGCAUAUGCGACGGCCAUGGACUGGUUCAUAGCCGUCUGUUAUG (SEQ ID NO: 6; GABRA3 variant 7). In some embodiments, the stem-loop sequence contains a GLURB-derived stem-loop as follows:

[0095] CAUUAAGGUGGGUGGAAUAGUAUACAAAGUAUCCCACCUACCCUGAUG (SEQ ID NO: 7; GLURB variant 8). In some embodiments, the stem-loop sequence contains the following GLURB-derived stem-loop:

[0096] CAUUAAGGUGGGUGGAAUAGUAUACAAAGUAUCCCACCUACCCCGAUG (SEQ ID NO: 8; GLURB variant 9). In some embodiments, the stem-loop sequence comprises the following GLURB-derived stem-loop:

[0097] UCCGUUUAGGUGGGUGGAAUAGUAAUACAAAGUAUCCCACCUACCCAGACG (SEQ ID NO: 9; GLURB variant 1).

[0098]

[0099]

[0100]

[0101]

[0102] Table 1 Natural editing sites

[0103] When the sensor RNA contains a nucleotide sequence comprising a stem-loop sequence (which contains a stop codon), the length of the stem-loop may be limited. For example, the stem-loop may be 50 bp or less, 40 bp or less, 30 bp or less, or 20 bp or less. In one embodiment, the length of the stem-loop is 18-50 bp.

[0104] Sensor RNAs containing nucleotide sequences containing stem-loop sequences (which contain editable codons) have certain advantages over sensor RNAs that do not contain such stem-loop sequences (such as those disclosed in International Application PCT / US2022 / 033459). This is because ADAR has separate domains for RNA editing (catalytic domain) and dsRNA binding. First, sensor RNAs containing nucleotide sequences containing stem-loop sequences (which contain editable codons) decouple the edited sequence (e.g., stop codon) from the sequence that recruits ADAR protein (i.e., the dsRNA fragment formed when the sensor nucleotide sequence hybridizes with the target RNA). Generally, if the editable codon in the sensor RNA is UAG (stop codon) and there is only one mismatch in the stop codon relative to the target RNA, the target RNA should have a CCA sequence (or a sequence that is reversely complementary to a different stop codon having a mismatch with the stop codon). The presence of a CCA sequence (or an equivalent sequence of different editable codons) may limit the number of possible target RNAs. Requiring the presence of a specific sequence (e.g., CCA or an equivalent sequence) in the target RNA can be limiting because it restricts which subsequences sensors can be created for; for example, CCA or an equivalent sequence may only be present in highly structured portions of the target RNA, may only be present in coding sequences, or may be present in the protein-binding portion of the target RNA, all of which may result in reduced availability of sensor-target hybridization and, therefore, reduced efficiency. Using sensors comprising stem-loops, the range of suitable subsequences is greatly increased, so problematic target RNA subsequences can be avoided and effective subsequences used instead. In some embodiments where it is necessary to distinguish between gene fusions or splice variants, flexibility in target RNA subsequence selection is desired, and stem-loop designs can provide this flexibility. Second, while ADAR editing is largely sequence-independent, there are some slight deviations, primarily driven by the catalytic domain, that extend beyond the range of editable codons. Catalytic domain driven bias is known in the art and has been described by, for example, Kuttan et al. (Proc Natl Acad Sci US A. 2012 Nov 27; 109(48): E3295-304), which is specifically incorporated herein by reference. The editing site in the sensor RNA may be determined by the target RNA, which prevents the optimization of the editing site (i.e., the stop or non-stop codon of the present disclosure). By separating the editing site from the sensor nucleotide sequence hybridized with the target RNA, the editing site and the sensor nucleotide sequence can be optimized separately.

[0105] In some embodiments, the sensor RNA comprises a non-start codon instead of a stop codon. In these embodiments, the sensor RNA comprises the following items: (i) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the target RNA, wherein the sensor nucleotide sequence comprises a non-start codon (e.g., AUA), the non-start codon comprises at least one base mismatched with the target RNA sequence, (ii) a second nucleotide sequence encoding a second cleavage domain, and (iii) a third nucleotide sequence encoding an output protein. In the presence of the target RNA, the sensor RNA hybridizes with the target RNA to form a double-stranded RNA molecule containing one or more base mismatches within or elsewhere in the non-start codon. Then, the ADAR protein edits the adenosine bases within the non-start codons of the sensor RNA (e.g., AUA to AUI) to inosine bases. This editing converts the non-start codon to a start codon, which then allows the output protein to be produced from the sensor RNA in the biological sample.

[0106] In some embodiments, the sensor RNA has a start codon instead of a stop codon. In these embodiments, the sensor RNA has the following items: (i) a first nucleotide sequence having a sensor nucleotide sequence that is reverse complementary to the target RNA, wherein the sensor nucleotide sequence has a start codon (e.g., AUG) that has at least one base mismatch with the target RNA sequence; and (ii) a second nucleotide sequence encoding an output protein, wherein the sequence encoding the output protein has a start codon. In the presence of the target RNA, the sensor RNA hybridizes with the target RNA to form a double-stranded RNA molecule with one or more base mismatches within the start codon or elsewhere. Then, the ADAR protein edits the adenosine base within the start codon of the sensor RNA (e.g., AUG to IUG) to an inosine base. The editing converts the start codon to a non-start codon, and then allows the output protein to be produced from the sensor RNA in the biological sample. Before editing, the presence of the first start codon in the sensor nucleotide sequence represents an upstream reading frame, which inhibits the expression of the downstream reading frame. After editing, the upstream reading frame is removed, thereby allowing the downstream reading frame to be expressed, thereby producing an output protein.

[0107] When the sensor RNA contains a start codon instead of a stop codon, the upstream reading frame as described above may have specific characteristics. In some embodiments, the length of the upstream reading frame is shorter than the downstream reading frame. In some embodiments, the length of the upstream reading frame is longer than the downstream reading frame. In one embodiment, the length of the upstream reading frame is about the same as the length of the downstream reading frame.

[0108] In some embodiments, the sensor RNA contains a start codon instead of a stop codon. In these embodiments, the sensor RNA comprises the following items: (i) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the target RNA, wherein the sensor nucleotide sequence comprises a start codon (e.g., AUG), which comprises at least one base mismatched with the target RNA sequence, and (ii) a second nucleotide sequence encoding an output protein. In the presence of the target RNA, the sensor RNA hybridizes with the target RNA to form a double-stranded RNA molecule containing one or more base mismatches in the start codon or elsewhere. Then, the ADAR protein edits the adenosine bases in the start codon of the sensor RNA (e.g., AUG to IUG) to inosine bases. The editing converts the start codon to a non-start codon, and then prevents the production of the output protein. In this embodiment, the output protein is produced only in the absence of the target RNA.

[0109] In some embodiments, the sensor RNA includes a splice site located before the exported protein. In these embodiments, the ADAR protein edits the codon at the splice site, thereby removing the splice site, resulting in the production of the exported protein. In some embodiments, the ADAR protein edits the non-splicing site, converting it into a splice site, thereby inhibiting the production of the exported protein.

[0110] In some cases, it is necessary to reduce the immunogenicity of the sensor RNA. Methods for reducing RNA immunogenicity are known in the art and have been described by, for example, Starostina et al. (Vaccines (Basel). 2021 May 3; 9 (5): 452), which is specifically incorporated herein by reference. In general, methods for reducing the immunogenicity of sensor RNA involve incorporating modified ribonucleic acids into sensor RNA. Modified ribonucleic acids that can be used in the present disclosure include, but are not limited to, methylcytosine, pseudouridine, methyladenosine, and the like. In some embodiments, methylcytosine is 5-methylcytosine. In some embodiments, pseudouridine is N1-methyl-pseudouridine. In some embodiments, methyladenosine is N6-methyladenosine. In some embodiments, methyladenosine is N1-methyladenosine. In some embodiments, a portion of the nucleotides present in the sensor RNA is composed of modified ribonucleic acids. For example, a portion of the uridine in the sensor RNA is replaced by pseudouridine. When the uridine of the sensor RNA is replaced by pseudouridine, a certain percentage of the uridine is replaced by pseudouridine. For example, about 1-10%, about 10-20%, about 20-30%, about 30-40%, about 40-50%, about 50-60%, about 60-70%, about 70-80%, 80-90%, or more than 90% of the uridines are replaced by pseudouridines. In one embodiment, 75% or less of the uridines in the sensor RNA are replaced by pseudouridines. In one embodiment, the sensor sequence has no pseudouridines.

[0111] When the sensor RNA contains pseudouridine, the pseudouridine may be located at a specific position. In some embodiments, the pseudouridine is not adjacent to an adenosine that is a target for ADAR editing. In some embodiments, the pseudouridine is not included in the sensor sequence that hybridizes with the target RNA. When the sensor RNA contains pseudouridine, the sensor may contain a specific stop codon. In some embodiments, the stop codon used is UGA. When the UGA stop codon is used, the adenosine in UGA may be followed by a specific nucleotide. In some embodiments, the adenosine in UGA is followed by guanosine, so the nucleotide sequence is UGAG.

[0112] In some embodiments, the sensor nucleotide sequence includes a base that mismatches with an adenosine base that is not within a start or stop codon in the target RNA. In some embodiments, the mismatched base prevents editing of adenosine that is not within a stop or start codon.

[0113] In some embodiments, the sensor nucleotide sequence includes one or more editing-inducing elements (EIEs). Suitable EIEs that can be used in the present disclosure are disclosed in Uzonyi et al. (Mol Cell. 2021 Jun 3; 81(11): 2374-2387) and Danan-Gotthold et al. (Genome Biol. 2017 Oct 23; 18(1): 196).

[0114] The marker protein of the present disclosure can be any marker protein that can be used to detect the presence of sensor mRNA in biological samples. For example, the marker protein can be a fluorescent protein or a luminescent protein. Non-limiting examples of useful fluorescent proteins include but are not limited to GFP, EBFP, Azurite, Cerulean, mCFP, Turquoise, ECFP, mKeima-Red, TagCFP, AmCyan, mTFP, TurboGFP, TagGFP, EGFP, TagYFP, EYFP, Topaz, Venus, mCitrine, TurboYFP, mOrange, TurboRFP, tdTomato, TagRFP, dsRed2, mRFP, mCherry, mPlum mRaspberry, mScarlet, etc. Examples of luminescent proteins include but are not limited to Cypridinia luciferase, Gaussia luciferase, Renilla luciferase, Phontinus luciferase, Luciola luciferase, Pyrophorus luciferase, Phrixothrix luciferase, etc. In some embodiments, the marker protein can be the first half of an export protein. In these embodiments, the sequence encoding the marker protein produces the first half of the export protein, which may be non-functional without the second half of the export protein in the absence of the target RNA. In the presence of the target RNA, the second half of the export protein is produced. When the second half of the export protein is produced in the presence of the first half of the export protein, the two halves are then able to form a functional export protein. In these embodiments, the first half of the export protein is the N-terminus of the export protein, and the second half of the export protein is the C-terminus of the export protein.

[0115] In certain embodiments, the sensor RNA includes a nucleotide sequence encoding a cleavage domain. The cleavage domains that can be used in the present disclosure include, but are not limited to, HIV-1 protease cleavage domains, TEV cleavage domains, preScission protease cleavage domains, HCV protease cleavage domains, RecA cleavage domains, self-cleavage domains, and the like. When a self-cleavage domain is used, the self-cleavage domain can be a 2A self-cleavage domain. The 2A self-cleavage domains that can be used in the present disclosure include T2A, P2A, E2A, and F2A described in Szymczak-Workman et al. (Cold Spring Harb Protoc. 2012 Feb 1; 2012 (2): 199-204). In some embodiments, the sensor RNA includes a first and a second cleavage domain. When the sensor RNA includes a first and a second cleavage domain, the cleavage domains can be of the same type or of different types. For example, the first cleavage domain can be a P2A self-cleavage domain and the second cleavage domain can also be a P2A self-cleavage domain, or the first cleavage domain can be a P2A self-cleavage domain and the second cleavage domain can also be a T2A self-cleavage domain, or any combination thereof.

[0116] The sensor nucleotide sequence of the present disclosure can be reverse complementary to any region of the target RNA. In certain embodiments, the sensor nucleotide sequence is reverse complementary to the 3'UTR of the target RNA. In some embodiments, the sensor nucleotide sequence is reverse complementary to the 5'UTR of the target RNA. In certain embodiments, the sensor nucleotide sequence is reverse complementary to the coding sequence of the target RNA. In some embodiments, the sensor nucleotide sequence is reverse complementary to the exon of the target RNA. In some embodiments, the sensor nucleotide sequence is reverse complementary to the intron of the target RNA. In some embodiments, the sensor nucleotide sequence is reverse complementary to two separate non-contiguous regions of the same target RNA. For example, the sensor nucleotide sequence can be reverse complementary to two separate regions of the 5'UTR of the target RNA, reverse complementary to two independent regions of the coding sequence of the target RNA, reverse complementary to two independent regions of the 5'UTR of the target RNA, reverse complementary to a region in the 5'UTR of the target RNA and a region in the coding sequence, reverse complementary to a region in the coding sequence of the target RNA and a region in the 3'UTR, or reverse complementary to a region in the 5'UTR of the target RNA and a region in the 3'UTR. In some embodiments, the sensor RNA is reverse complementary to two or more different target RNAs.

[0117] Sensor RNAs with sensor nucleotide sequences that are reverse complementary to 3' or 5' UTRs have certain advantages over sensor RNAs that are reverse complementary to coding sequences (CDS), such as the sensor RNAs disclosed in International Application PCT / US2022 / 033459. First, ADAR editing is more efficient in UTRs compared to CDSs because translating ribosomes may destabilize dsRNAs. Figure 4D Second, RADARs are unlikely to interfere with the production of the protein encoded by the target RNA because 1) dsRNA formation in the UTR rather than the CDS does not affect the translating ribosome, and 2) any bystander editing that occurs in the UTR of the target RNA is unlikely to lead to deleterious consequences because the coding sequence will not be edited.

[0118] The sensor nucleotide sequences of the present disclosure can be any length necessary to have sufficient specificity for the target RNA. For example, the sensor nucleotide sequence can be less than about 50 nucleotides, about 50 to 60, about 60 to 70, about 70 to 80, about 80 to 90, about 90 to 100, about 100 to 110, about 110 to 120, about 120 to 130, about 130 to 140, about 140 to 150, about 150 to 160, about 160 to 170, about 170 to 180, about 180 to 190, about 190 to 200, about 200 to 210, about 210 to 220, about 220 to 230, about 230 to 240, about 240 to 250, about 250 to 260, about 260 to 270, about 270 to 280, about 280 to 290, about 300 to 310, about 310 to 320, about 320 to 330, about 330 to 340, about 350 to 360, about 360 to 370, about 380 to 390, about 400 to 410, about 410 to 420, about 420 to 430, about 430 to 440, about 450 to 460, about 460 to 470, about 480 to 490, about 500 to 510 430, about 440-450, about 450-460, about 460-470, about 470-480, about 480-490, about 490-500, about 500-510, about 510-520, about 520-530, about 530-540, about 540-550, about 550-560, about 560-570, about 570-580, about 580-590, about 590-600, about 600-610, about 600-611, about 600-620, about 600-630, about 600-640, about 600-650, about 600-660, about 600-670, about 600-680, about 600-690, about 600-70

[0119] When the sensor nucleotide sequence is reverse complementary to two discontinuous regions within the target RNA, the distance between the two discontinuous regions of the target can be of any length. For example, the distance between the two discontinuous regions of the target can be less than about 50 nucleotides, about 50 to 60 nucleotides, about 60 to 70 nucleotides, about 70 to 80 nucleotides, about 80 to 90 nucleotides, about 90 to 100 nucleotides, about 100 to 150 nucleotides, about 150 to 200 nucleotides, about 200 to 250 nucleotides, about 250 to 300 nucleotides, about 300 to 350 nucleotides, about 350 to 400 nucleotides, about 400 to 450 nucleotides, about 450 to 500 nucleotides, or greater than 500 nucleotides.

[0120] When the sensing nucleotide sequence is reverse complementary to two discontinuous regions within the target RNA, the nucleotide sequence of the sensing nucleotide that is reverse complementary to the first region of the two discontinuous regions of the target RNA may be of any length. For example, the nucleotide sequence of the sensor nucleotide that is reverse complementary to the first region of the two discontinuous regions can be less than about 20 nucleotides, about 20 to 30, about 30 to 40, about 40 to 50, about 50 to 60, about 60 to 70, about 70 to 80, about 80 to 90, about 90 to 100, about 100 to 110, about 110 to 120, about 120 to 130, about 130 to 140, about 140 to 150, about 150 to 160, about 160 to 170, about 170 to 180, about 180 to 190, about 190 to 200, about 200 to 210, about 210 to 220, about 220 to 230, about 230 to 240, about 240 to 250, about 250 to 260, about 260 to 270, about 270 to 280, about 280 to 290, about 290 to 300, about 300 to 310, about 310 to 320, about 320 to 330, about 330 to 340, about 350 to 360 400-410, about 410-420, about 420-430, about 430-440, about 440-450, about 450-460, about 460-470, about 470-480, about 480-490, about 490-500, or greater than 500 nucleotides in length.

[0121] When the sensing nucleotide sequence is reverse complementary to two discontinuous regions of the target RNA, the nucleotide sequence of the sensing nucleotide that is reverse complementary to the second region of the two discontinuous regions of the target RNA may be of any length. For example, the nucleotide sequence of the sensor nucleotide that is reverse complementary to the second region of the two discontinuous regions may be less than about 20 nucleotides, about 20 to 30, about 30 to 40, about 40 to 50, about 50 to 60, about 60 to 70, about 70 to 80, about 80 to 90, about 90 to 100, about 100 to 110, about 110 to 120, about 120 to 130, about 130 to 140, about 140 to 150, about 150 to 160, about 160 to 170, about 170 to 180, about 180 to 190, about 190 to 200, about 200 to 210, about 210 to 220, about 220 to 230, about 230 to 240, about 240 to 250 400-410, about 410-420, about 420-430, about 430-440, about 440-450, about 450-460, about 460-470, about 470-480, about 480-490, about 490-500, or greater than 500 nucleotides in length.

[0122] The sensor nucleotide sequence or stem-loop of the present disclosure may include any stop or start codon, including an adenosine residue. For example, the stop codon of the sensor nucleotide sequence may be UAG, UAA, or UGA. Generally speaking, the stop codon of the present disclosure is in frame with the coding sequence of the export protein, such that when the stop codon is edited, the export protein is produced.

[0123] The output protein of the present disclosure can be any desired output protein. Examples of the output protein of the present disclosure include, but are not limited to, fluorescent proteins, genome modification proteins, transcription factors, killer factors, toxins, antigens, T cell receptors, enzymes, therapeutic proteins, cytokines, chemokines, growth factors, signal peptides, chimeric antigen receptors (CAR), etc. The output protein can be secreted, transmembrane or membrane bound. When the output protein is to be transported to a specific location in a biological sample, the coding sequence of the output protein is preceded by a nucleotide sequence encoding an appropriate signal peptide, such as those described in Owji et al. (Eur J Cell Biol. 2018Aug; 97 (6): 422-441).

[0124] When the export protein is a genome modification protein, the genome modification protein may include, but is not limited to, CRE recombinase or variants thereof, meganuclease or variants thereof, zinc finger nuclease or variants thereof, CRISPR / Cas-9 nuclease or variants thereof, modified Cas9 nickase fused to reverse transcriptase (i.e., genome modification protein used in primary editing), TAL effector nuclease or variants thereof, etc. Methods for primary editing are known in the art and have been described, for example, in Scholefield et al. (Gene Ther. 2021 Aug; 28(7-8): 396-401), which is specifically incorporated herein by reference.

[0125] When the export protein is a transcription factor, the transcription factor may include, but is not limited to, jun, fos, max, mad, serum response factor (SRF), AP-1, AP2, myb, MyoD, myogenin, ETS-box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, 5HNF4, C / EBP, SP1, CCAAT-box binding protein, interferon regulatory factor (IRF-1), Wilms tumor protein, ETS binding protein, STAT, GATA-box binding protein (e.g., GATA-3), and the forkhead family of winged helix proteins.

[0126] When the exported protein is a killing factor, the killing factor may include, but is not limited to, tumor necrosis factor alpha (TNFa), Fas ligand (FasL), caspases such as caspase 1, caspase 2, caspase 3, caspase 4, caspase 5, caspase 6, caspase 7, caspase 8, caspase 9, caspase 10, caspase 11, caspase 12, caspase 13 or variants thereof, etc.

[0127] When the exported protein is a therapeutic protein, the therapeutic protein may include, but is not limited to, hormones and growth and differentiation factors, including, but not limited to, insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GHRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiostatin, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), transforming growth factor alpha (TGFa), platelet-derived growth factor (PDGF), any of the insulin-like growth factors I and II (IGF-1 and IGF-11), transforming growth factor 13 superfamily, including TGFI3, activin, inhibin, or any bone morphogenetic protein (BMP) (including BMP 1-15), any of the heregluin / neuregulin / ARIA / neu differentiation factor (NDF) family of growth factors, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophins NT-3 and NT-4 / 5, ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophins, agrin, any of the semaphorin / disintegrator family, netrin-1 and netrin-2, hepatocyte growth factor (HGF), ephrins, noggin, sonic hedgehog, and tyrosine hydroxylase.

[0128] When the exported protein is a cytokine, the cytokine may include, but is not limited to, IL-1-like, IL-1α, IL-1β, IL-1RA, IL-18, CD132, IL-2, IL-4, IL-7, IL-9, IL-13, CD1243, 132, IL-15, CD131, IL-3, IL-5, GM-CSF, IL-6-like, IL-6, IL-11, G-CSF, IL-12, LIF, OSM, IL-10-like, IL-10, IL-20 , IL-14, IL-16, IL-17, IFN-α, IFN-β, IFN-γ, CD154, LT-β, ​​TNF-α, TNF-β, 4-1BBL, APRIL, CD70, CD153, CD178, GI TRL, LIGHT, OX40L, TALL-1, TRAIL, TWEAK, TRANCE, TGF-β1, TGF-β2, TGF-β3, Epo, Tpo, Flt-3L, SCF, M-CSF, MSP, etc.

[0129] When the exported protein is a chemokine, the chemokine may include, but is not limited to, XCL1, XCL2, CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CX3CL1, and the like.

[0130] In certain embodiments, when the output polypeptide is CAR, the extracellular binding domain of CAR has a single-chain antibody. Single-chain antibodies can be monoclonal single-chain antibodies, chimeric single-chain antibodies, humanized single-chain antibodies, fully human single-chain antibodies, etc. In a non-limiting example, single-chain antibodies are single-chain variable fragments (scFv). Suitable CAR extracellular binding domains include those described in Labanieh et al. (2018Nature Biomedical Engineering 2: 377-391), which are specifically incorporated herein by reference. In some embodiments, the extracellular binding domain of CAR is a single-chain version (e.g., scFv version) of an antibody approved for use as a therapeutic antibody by the U.S. Food and Drug Administration and / or the European Medicines Agency (EMA), for example, for inducing antibody-dependent cellular toxicity (ADCC) of certain disease-related cells in patients, etc. Non-limiting examples of single chain antibodies that can be employed when the protein of interest is a CAR include Adecatumumab, Ascrinvacumab, Cixutumumab, Conatumumab, Daratumumab, Drozitumab, Duligotumab, Durvalumab, Dusigitumab, Enfortumab, Enoticumab, Figitumumab, Ganitumab, Glembatumumab, Intetumumab, Ipilimumab, Iritutumab, atumumab), Icrucumab, Lexatumumab, Lucatumumab, Mapatumumab, Narnatumab, Necitumumab, Nesvacumab, Ofatumumab, Olaratumab, Panitumumab, Patritumab, Pritumumab, Radretumab, Ramucirumab, Rilotumumab, Robatumumab, Seribantumab, Tarextumab,Teprotumumab, Tovetumab, Vantictumab, Vesencumab, Votumumab, Zalutumumab, Flanvotumab, Altumomab, Anatumomab, Arcitumomab, Bectumomab, Blinatumomab, Detumomab, Ibritumomab tumomab), Minretumomab, Mitumomab, Moxetumomab, Naptumomab, Nofetumomab, Pemtumomab, Pintumomab, Racotumomab, Satumomab, Solitomab, Taplitumomab, Tenatumomab, Tositumomab ab), Tremelimumab, Abagovomab, Igovomab, Oregovomab, Capromab, Edrecolomab, Nacolomab, Amatuximab, Bavituximab, Brentuximab, Cetuximab, Derlotuximab, Dinutuximab, Entuuximab nsituximab), Futuximab, Girentuximab, Indatuximab, Isatuximab, Margetuximab, Rituximab, Siltuximab, Ublituximab, Ecormeximab, Abituzumab, Alemtuzumab, Bevacizumab, Bivatuzumab,Brontictuzumab, Cantuzumab, Cantuzumab, Citatuzumab, Clivatuzumab, Dacetuzumab, Demcizumab, Dalotuzumab, Denintuzumab, Elotuzumab, Emactuzumab, Emibetuzumab, Enoblituzumab, Elotuzumab Etaracizumab, Farletuzumab, Ficlatuzumab, Gemtuzumab, Imgatuzumab, Inotuzumab, Labetuzumab, Lifastuzumab, Lintuzumab, Lorvotuzumab, Lumretuzumab, Matuzumab, Milatuzumab mab), Nimotuzumab, Obinutuzumab, Ocaratuzumab, Otlertuzumab, Onartuzumab, Oportuzumab, Parsatuzumab, Pertuzumab, Pinatuzumab, Polatuzumab, Sibrotuzumab, Simtuzumab, Tacapizumab acatuzumab), Tigatuzumab, Trastuzumab, Tucotuzumab, Vandortuzumab, Vanucizumab, Veltuzumab, Vorsetuzumab, Sofituzumab, Catumaxomab, Ertumaxomab, Depatuxizumab, Ontuxizumab,Single chain versions (e.g., scFv versions) of Blontuvetmab, Tamtuvetmab, or antigen-binding variants thereof.

[0131] The exported protein may also include a tag for detecting the production of the protein after it is produced. For example, the tag may include, but is not limited to, fluorescent proteins, such as green fluorescent protein (GFP), YFP, RFP, CFP, mCherry, tdTomato, etc.; histidine tags, such as 6XHis tags; hemagglutinin (HA) tags; FLAG tags; Myc tags, etc.

[0132] In some embodiments, detection is quantitative or qualitative. For example, the detection of target RNA can be related to the amount of the output protein produced. In some embodiments, the amount of the output protein can be linear relative to the amount of the target RNA. In some embodiments, the amount of the output protein can be logarithmic relative to the amount of the target RNA. The disclosed method can detect the change of specific gene expression by detecting the target RNA quantitative detection. For example, the method can detect about 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times, 200 times, 300 times, 400 times, 500 times, 600 times, 700 times, 800 times, 900 times, 1000 times, 5000 times, 10,000 times, 50,000 times, 100,000 times or more than 100,000 times of change in the target RNA.

[0133] Aspects of the present disclosure include determining the presence of an export protein in a biological sample. In some embodiments, determining the export protein may comprise the use of immunoblotting. In some embodiments, determining comprises the use of microscopy. When determining comprises microscopy, the export protein may be conjugated to a fluorescent or luminescent protein, or the export protein may be a fluorescent or luminescent protein. In some embodiments, determining the presence of an export protein comprises the use of flow cytometry. When determining comprises flow cytometry, fluorescence activated cell sorting may be used.

[0134] The method of the present disclosure also includes combining the biological sample with the sensor RNA. Any convenient method known in the art can be used for combination. In some embodiments, the combination includes transfecting the biological sample with a recombinant vector containing the sensor RNA. When the biological sample is transfected with a recombinant vector, the recombinant vector includes but is not limited to a plasmid, a viral vector, a cosmid, an artificial chromosome, etc. In some embodiments, the combination includes contacting the biological sample with a lipid nanoparticle containing the sensor RNA. Lipid nanoparticles have been described in the art, such as Hou et al. (Nat Rev Mater. 2021; 6 (12): 1078-1094).

[0135] When it is necessary to transfect a biological sample such as a cell, a vector (such as a plasmid virus vector, a cosmid or an artificial chromosome) can be used to engineer the cell so that it expresses the sensor RNA as required. Interested protocols include those described in published PCT application WO1999 / 041258, the disclosure of which is incorporated herein by reference.

[0136] Depending on the nature of the cells and / or expression constructs, protocols of interest may include electroporation, particle gun technology, calcium phosphate precipitation, direct microinjection, viral infection, and the like. The choice of method generally depends on the type of cell being transformed and the environment in which the transformation occurs (i.e., in vitro, ex vivo, or in vivo). A general discussion of these methods can be found in Ausubel et al. Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons, 1995. In some embodiments, lipofectamine and calcium-mediated gene transfer techniques are used. After the subject nucleic acid is introduced into the cell, the cell may be incubated, typically at 37° C., sometimes under selection for about 1-24 hours, to allow expression of the sensor RNA. In mammalian target cells, many viral-based expression systems may be used to express the sensor RNA. In the case of using an adenovirus as an expression vector, the sensor RNA sequence of interest may be connected to an adenovirus transcription / translation control complex, such as a late promoter and a tripartite leader sequence. The chimeric gene may then be inserted into the adenovirus genome by in vitro or in vivo recombination. Insertion into a non-essential region of the viral genome (e.g., region E1 or E3) will produce a recombinant virus that is viable and capable of expressing the chimeric protein in an infected host. (See, for example, Logan & Shenk, Proc. Natl. Acad. Sci. USA 81: 355-359 (1984)). Expression efficiency can be enhanced by adding appropriate transcription enhancer elements, transcription terminators, etc. (See Bittner et al., Methods in Enzymol. 153: 51-544 (1987)).

[0137] In some embodiments, the viral vector is a recombinant adeno-associated virus (AAV) vector. AAV vectors are relatively small DNA viruses that can be integrated into the genome of the cells they infect in a stable and site-specific manner. They are able to infect a wide range of cells without any effect on cell growth, morphology or differentiation, and they do not seem to be associated with human pathology. The AAV genome has been cloned, sequenced and characterized. It contains approximately 4700 bases and an inverted terminal repeat (ITR) region of approximately 145 bases at each end, which serves as the origin of viral replication. The rest of the genome is divided into two basic regions that carry capsid function: the left portion of the genome, comprising the rep gene involved in viral replication and viral gene expression; and the right portion of the genome, comprising the cap gene encoding viral capsid protein.

[0138] In recent years, the application of AAV as a gene therapy vector has developed rapidly. Wild-type AAV can infect dividing or non-dividing cells or tissues of mammals, including humans, at a high titer, and can also be integrated into specific sites of human cells (on the long arm of chromosome 19) (Kotin et al., Proc. Natl. Acad. Sci. USA, 1990. 87: 2211-2215; Samulski et al., EMBO J., 1991. 10: 3941-3950, the disclosure of which is incorporated herein by reference in its entirety). AAV vectors without rep and cap genes lose site-specific integration, but can still mediate long-term stable expression of exogenous genes. AAV vectors exist in cells in two forms, one is an extrachromosomal free form; the other is integrated into chromosomes, and the former is the main form. In addition, AAV has not yet been found to be associated with any human disease, and no changes in biological properties caused by integration have been observed. There are currently 16 serotypes of AAV reported in the literature, named AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, and AAV16. Among them, AAV5 was originally isolated from humans (Bantel-Schaal, and H. zur Hausen. Virology, 1984. 134: 52-63), and AAV1-4 and AAV6 were discovered in adenovirus research (Ursula Bantel-Schaal, Hajo Delius and Harald zur Hausen. J. Viral., 1999. 73: 939-947).

[0139] AAV vectors can be prepared using any convenient method. Any serotype of adeno-associated virus is suitable (see, e.g., Blacklow, pp. 165-174 of "Parvoviruses and Human Disease" JR Pattison, ed. (1988); Rose, Comprehensive Virology 3:1, 1974; P. Tattersall "The Evolution of Parvovirus Taxonomy" In Parvoviruses (JR Kerr, SF Cotmore. ME Bloom, RM Linden, CR Parrish, Eds.) p 5-14, Rudder Arnold, London, UK (2006); and DE Bowles, J E Rabinowitz, RJ Samulski "The Genus Dependovirus" (JR Kerr, SF Cotmore. ME Bloom, RM Linden, CR Parrish, Eds.) p 15-23, Rudder Arnold, London, UK (2006), the disclosures of which are hereby incorporated by reference herein). Methods for purifying vectors can be found in, for example, U.S. Pat. Nos. 6,566,118, 6,989,264, and 6,995,006 and WO / 1999 / 011764 entitled "Methods for Generating High Titer Helper-free Preparation of Recombinant AAV Vectors," the disclosure of which is incorporated herein by reference in its entirety. The preparation of hybrid vectors is described, for example, in PCT Application No. PCT IUS2005 / 027091, the disclosure of which is incorporated herein by reference in its entirety. The use of viral vectors derived from AAV for transferring genes in vitro and in vivo has been described (see, for example, International Patent Application Publication Nos. 91 / 18088 and WO93 / 09239; U.S. Pat. Nos. 4,797,368, 6,596,535, and 5,139,941; and European Patent No. 0488528, all of which are incorporated herein by reference in their entirety). These disclosures describe various AAV-derived constructs in which the rep and / or cap genes are deleted and replaced with a gene of interest, and the use of these constructs to transfer a gene of interest in vitro (into cultured cells) or in vivo (directly into an organism).The replication-deficient recombinant AAV of the present invention can be prepared by co-transfecting a plasmid containing a target nucleic acid sequence (flanked by two AAV inverted terminal repeat (ITR) regions) and a plasmid carrying AAV capsid genes (rep and cap genes) into a cell line infected with a human helper virus (e.g., adenovirus). The resulting AAV recombinant is then purified by standard techniques.

[0140] In some embodiments, the vectors used in the methods of the invention are encapsulated into viral particles (e.g., AAV viral particles, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, and AAV16). Thus, the invention includes recombinant viral particles (recombinant because they contain recombinant polynucleotides) comprising any of the vectors described herein. Methods for producing such particles are known in the art and are described in U.S. Pat. No. 6,596,535.

[0141] When the biological sample is transfected with the recombinant vector containing the sensor RNA, the sensor RNA is operably linked to the promoter. Suitable promoters disclosed herein include, but are not limited to, SFFV promoter, hEF1a, CMV promoter or variants thereof, inducible promoter, CMV-tetO promoter, tissue or cell specific promoter, etc.

[0142] In some aspects of the present disclosure, the sensor RNA includes one or more MS2 hairpins. In some embodiments, the sensor RNA includes more than one MS2 hairpin. For example, the sensor RNA may include two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, or more than ten. In some aspects, the sensor RNA includes one or more TAR RNA elements. For example, the sensor RNA may include two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, or more than ten. In some aspects, the sensor RNA includes one or more BoxB stem loops. For example, the sensor RNA may include two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, or more than ten. In some aspects, the sensor RNA includes MS2 hairpins and BoxB stem loops, MS2 hairpins and TAR RNA elements, or BoxB stem loops and TAR RNA elements.

[0143] In some embodiments, the method for detecting target RNA further comprises combining biological sample with ADAR protein or its coding sequence.ADAR protein can be any ADAR protein from any species.For example, ADAR protein can include but is not limited to ADAR (ADAR1), ADAR p110, ADAR p150, ADAR2, engineered ADAR protein (e.g., protein containing the deaminase domain of ADAR2 or its variant and MS2 RNA binding protein (MCP)), lacking the engineered ADAR protein of nuclear localization sequence, engineered ADAR protein containing nuclear export sequence, engineered ADAR protein containing one or more dsRNA binding domains from one or more different ADAR proteins, engineered ADAR protein containing TAR RNA binding protein, engineered ADAR protein containing Lambda N peptide, wherein the N-terminal and C-terminal of deaminase domain are respectively produced and two halves are mutually bound in the presence of target RNA segmented engineered ADAR protein etc. Suitable engineered ADAR proteins are described in Katrekar et al. (Nat Methods. 2019 Mar; 16 (3): 239-242.), Biswas et al. (iScience. 2020 Jul 24; 23 (7): 101318), Matthews et al. (Nat Struct Mol Biol. 2016 May; 23 (5): 426-33), Cox et al. (Science. 2017 Nov 24; 358 (6366): 1019-1027) or Kuttan et al. Proc Natl Acad Sci U SA. 2012 Nov 27; 109 (48): E3295-304). Katrekar et al. (Elife. 2022 Jan 19; 11: e75555) describe segmented engineered ADAR proteins. When the sensor RNA contains a start codon instead of a stop codon, a specific ADAR protein can be used. In some embodiments, when the sensor RNA comprises a start codon instead of a stop codon, the ADAR protein is ADAR2.

[0144] In some embodiments, RNA editing proteins other than ADARs are used. For example, proteins of the apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) family can be used. Examples of suitable APOBEC proteins include, but are not limited to, APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4, and the like.

[0145] In some embodiments, the sensor RNA further comprises a nucleotide sequence containing a cleavage domain, which is followed by a nucleotide sequence encoding any of the above-mentioned ADAR proteins, wherein the nucleotide sequence containing the cleavage domain is located after the nucleotide sequence encoding the export protein. In some embodiments, an ADAR protein is used instead of a marker protein as the first nucleotide sequence.

[0146] In some embodiments, the sensor RNA further comprises a nucleotide sequence encoding a second sensor nucleotide sequence that is reverse complementary to a second target RNA, wherein the sensor nucleotide sequence comprises a second stop codon, wherein the sequences of the first and second target RNAs are different. In some embodiments, the stop codon comprises at least one base that is mismatched with the second target RNA sequence. In some embodiments, the sensor RNA further comprises a nucleotide sequence encoding a second sensor nucleotide sequence that is reverse complementary to the second target RNA, wherein the sensor nucleotide sequence comprises a start codon. In some embodiments, the sensor RNA further comprises a nucleotide sequence encoding a second sensor nucleotide sequence that is reverse complementary to the second target RNA, wherein the sensor nucleotide sequence comprises a non-start codon that can be edited as a start codon. In some embodiments, the stop, start or non-start codon comprises at least one base that is mismatched with the second target RNA sequence. In some embodiments, the stop, start or non-start codon is contained in a stem-loop sequence contained in the second sensor nucleotide sequence. In some embodiments, the biological sample is combined with two or more sensor RNAs that detect two or more different target RNAs.

[0147] In some embodiments, the method for detecting the target RNA further comprises combining the biological sample with a protein that specifically locates the sensor RNA to the target RNA position. For example, the protein that specifically locates the sensor RNA to the target RNA position can be a dCas9 or dCas13 protein, which has a guide RNA for a genomic site corresponding to the target RNA (in the case of dCas9) or directly for the target RNA (in the case of dCas13). In some embodiments, dCas9 or dCas13 is engineered to be connected to MCP, TAR RNA binding protein or Lambda N peptide.

[0148] Methods for expressing proteins in target cells

[0149] As described above, there is provided a method of expressing a protein in a target cell, the method comprising combining the cell with a sensor RNA as described above, wherein the target RNA is present in the target cell.

[0150] In some cases, the target RNA hybridized with the sensor RNA is determined by the target cell. In some embodiments, the target cell is a cell in a specific disease state. In these cases, the target cell includes a target RNA specific to the disease state, or a target RNA with higher abundance in a cell (such as a cancer cell) in a specific disease state. The cell can be in any disease state. In some embodiments, the target cell is a specific cell type. In these cases, the target cell includes a target RNA specific to a cell type, or a target RNA with higher abundance in a cell of a specific cell type. The cell can be any cell type.

[0151] Cells from any source are candidate cells for combination with the sensor RNA of the present disclosure. Non-limiting examples of candidate cell types include connective tissue elements such as fibroblasts, skeletal tissue (bone and cartilage), bones, heart and smooth muscle, epithelial tissue (e.g., liver, lungs, breast, skin, bladder and kidneys), neural cells (glial cells and neurons), endocrine cells (adrenal glands, pituitary glands, pancreatic islet cells), bone marrow cells, melanocytes and many different types of hematopoietic cells. Suitable cells can also be cells representing specific body tissues of the subject. The types of body tissues include, but are not limited to, blood, muscle, nerve, brain, heart, lung, liver, pancreas, spleen, thymus, esophagus, stomach, intestine, kidney, testis, ovary, hair, skin, bone, breast, uterus, bladder, spinal cord and various body fluids.

[0152] Cells suitable for the subject methods include cells of a variety of test hosts. Typically, such test hosts are "mammals," terms widely used to describe organisms in the class Mammalia, including Carnivora (e.g., dogs and cats), Rodentia (e.g., mice, guinea pigs, and rats), and Primates (e.g., humans, chimpanzees, and monkeys). In many aspects, the test host will be a human. In certain embodiments, the test host is a plant.

[0153] In certain embodiments, the method for expressing the target protein in the target cell also includes combining the biological sample with an ADAR protein or its coding sequence. The ADAR protein can be any ADAR protein from any species. For example, the ADAR protein can include but is not limited to ADAR (ADAR1), ADAR p110, ADAR p150, ADAR2, engineered ADAR proteins (such as proteins including the deaminase domain of ADAR2 or its variants and MS2 RNA binding protein MCP, etc.). Suitable engineered ADAR proteins have been described in Katrekar et al. (Nat Methods. 2019 Mar; 16(3): 239-242.), Biswas et al. (iScience. 2020 Jul 24; 23(7): 101318), Matthews et al. (Nat Struct Mol Biol. 2016 May; 23(5): 426-33), Cox et al. (Science. 2017 Nov 24; 358(6366): 1019-1027), or Kuttan et al. (Proc Natl Acad Sci U SA. 2012 Nov 27; 109(48): E3295-304).

[0154] The method of expressing protein in target cells includes combining target cells with sensor RNA. Any convenient method known in the art can be used for combination. In some embodiments, the combination includes transfecting the biological sample with a recombinant vector including the sensor RNA. When the biological sample is transfected with a recombinant vector, the recombinant vector includes but is not limited to plasmids, viral vectors, cosmids, artificial chromosomes, etc. In some embodiments, the combination includes contacting the biological sample with lipid nanoparticles including the sensor RNA. Lipid nanoparticles have been described in the art, such as Hou et al. (Nat Rev Mater. 2021; 6 (12): 1078-1094).

[0155] When it is necessary to transfect a biological sample such as a cell, a vector (such as a plasmid viral vector, a cosmid or an artificial chromosome) can be used to engineer the cell to express the sensor RNA as desired.

[0156] The protein expressed in the target cell is an export protein encoded by the sensor RNA. The export protein of the sensor RNA can be any of the export proteins described above. In some embodiments, the export protein treats a disease or condition associated with the target RNA in the target cell.

[0157] In some embodiments, the method of the present disclosure can be used to produce a target protein in the absence of cells. In these embodiments, the cell-free system includes a biological sample, a sensor RNA, and an ADAR protein. The biological sample can include any target RNA. For example, the biological sample can be a sample including viral material (such as viral RNA), wherein the detection of viral RNA leads to the production of exported proteins. Suitable cell-free systems include Kuruma et al. (Nat Protoc. 2015 Sep; 10 (9): 1328-44) and Lavickova et al. (ACS Synth Biol. 2019 Feb 15; 8 (2): 455-462) described systems.

[0158] Methods of treating a disease or condition

[0159] The method of expressing protein in target cells can also be used to treat individual diseases or conditions. In the methods disclosed herein, the protein expressed in the target cells can promote the survival of the target cells or can promote the death of the cells. For example, if the disease or condition is related to cells infected by pathogens or cancer cells, it may be desirable to promote the death of such cells. In the embodiment where the target cell death is desired, the output protein encoded by the sensor RNA can be any output protein that promotes cell death. The output protein that promotes cell death includes but is not limited to toxins, tumor necrosis factor alpha (TNFa), Fas ligand (FasL), caspase such as caspase 1, caspase 2, caspase 3, caspase 4, caspase 5, caspase 6, caspase 7, caspase 8, caspase 9, caspase 10, caspase 11, caspase 12, caspase 13 or its variants, etc.

[0160] In addition, if the disease or condition is related to cells infected by pathogens or cancer cells, it may also be necessary to activate immune cells to target the infected cells or cancer cells. Immune cells generally include white blood cells, which are derived from hematopoietic stem cells (HSC) produced in the bone marrow. Immune cells also include, for example, lymphocytes (T cells, B cells, natural killer (NK) cells) and bone marrow-derived cells (neutrophils, eosinophils, basophils, monocytes, macrophages, dendritic cells). T cells include all types of immune cells expressing CD3, including T helper cells (CD4 + cells), cytotoxic T cells (CD8 + cells), T regulatory cells (Treg) and gamma delta T cells. Cytotoxic cells include CD8 + T cells, natural killer (NK) cells, and neutrophils, which are capable of mediating cytotoxic responses.

[0161] In the embodiment where it is necessary to activate immune cells, the target RNA to which the sensor RNA is directed can be a target RNA specifically expressed in immune cells. In the embodiment where it is necessary to activate immune cells, the sensor RNA can include a sequence encoding an output protein that activates or regulates the activity of immune cells. Non-limiting examples of output proteins that activate immune cells include chimeric antigen receptors, such as those described above, or cytokines, such as L-1-like, IL-1α, IL-1β, IL-1RA, IL-18, CD132, IL-2, IL-4, IL-7, IL-9, IL-13, CD1243, 132, IL-15, CD131, IL-3, IL-5, GM-CSF, IL-6-like, IL-6, IL-11, G-CSF, IL-12, LIF, OSM, IL-10-like, I L-10, IL-20, IL-14, IL-16, IL-17, IFN-α, IFN-β, IFN-γ, CD154, LT-β, ​​TNF-α, TNF-β, 4-1BBL, APRIL, CD70, CD153, CD1 78. GITRL, LIGHT, OX40L, TALL-1, TRAIL, TWEAK, TRANCE, TGF-β1, TGF-β2, TGF-β3, Epo, Tpo, Flt-3L, SCF, M-CSF, MSP, etc.

[0162] If the disease or condition is associated with the expression of a non-functional protein, a protein with reduced function, or a protein that has abnormal activity in the disease state relative to the non-disease state, it may be desirable to have a sensor RNA that is targeted to the diseased cells, wherein upon contact with the diseased cells containing the target RNA, the cells produce an exported protein, wherein the exported protein is a fully functional form of the non-functional, reduced function, or abnormally functional protein.

[0163] If the disease or condition is associated with tissue degeneration, it may be desirable to promote the growth or regeneration of said tissue. In embodiments where the disease or condition is associated with tissue degeneration, it may be desirable to have a sensor RNA that is directed to diseased cells, wherein upon contact with the diseased cells containing the target RNA, the cells produce an export protein that promotes tissue growth or regeneration. Non-limiting examples of export proteins that promote tissue growth or regeneration include hormones and growth and differentiation factors, including but not limited to insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GHRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiostatin, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), transforming growth factor alpha (TGFa), platelet-derived growth factor (PDGF), insulin-like growth factor I and II (IGF-1 and IGF-11), any of the transforming growth factor 13 superfamily, including TGFI3, activin, inhibin, or any bone morphogenetic protein (BMP) (including BMP 1-15), any of the heregluin / neuregulin / ARIA / neu differentiation factor (NDF) family of growth factors, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophins NT-3 and NT-4 / 5, ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor (GDNF), neurotrophins, agrin, any of the semaphorin / disintegrator family, netrin-1 and netrin-2, hepatocyte growth factor (HGF), ephrins, noggin, sonic hedgehog, and tyrosine hydroxylase.

[0164] Given the diversity of cellular activities that can be modulated using the subject sensor RNA, the present therapeutic methods can be used for a variety of applications. As non-limiting examples, the present methods can be used to treat a variety of diseases, including, but not limited to, for example, Acanthamoeba infection, Acinetobacter infection, adenovirus infection, ADHD (attention deficit / hyperactivity disorder), AIDS (acquired immunodeficiency syndrome), ALS (amyotrophic lateral sclerosis), Alzheimer's disease, intestinal amebiasis (infection with Entamoeba histolytica), human anaplasmosis, anemia, angiostrongylus infection, animal-related diseases, seahorse nematode infection (seahorse nematode disease), anthrax, aortic aneurysm, aortic dissection, arenavirus infection, arthritis (e.g., childhood arthritis, fibromyalgia, gout, lupus (SLE) (systemic lupus erythematosus), osteoarthritis, rheumatoid arthritis, etc.), roundworm infection ( Ascariasis), Aspergillus infection (Aspergillosis), Asthma, Attention-Deficit / Hyperactivity Disorder, Autism, Bird Flu, B virus infection (Herpes B virus), Burkholderia cepacia infection (Burkholderia cepacia infection), Babesiosis (Babesia infection), Bacterial meningitis, Bacterial vaginosis (BV), Balmuthia infection (Balmuthia mandela infection), Balmuthia mandela infection, Balmonia infestation, Balmonia infestation (Balmuthiasis), Baylisascaris infection, Schistosomiasis, Birth defects, Black lung (Coal workers' pneumoconiosis), Blastocystis hominis infection, Blastocystis infection, Blastomycosis, Bleeding disorders, Blood disorders, Body lice (Borrelia hominis), Borrelia burgdorferi infection, Botulism (Botulinum toxin Clostridium difficile), bovine spongiform encephalopathy (BSE), Brainard diarrhea, breast cancer, bronchiolitis, bronchitis, Brucella infection (brucellosis), Brucellosis, Burkholderia cepacia infection (Burkholderia cepacia infection), Burkholderia glanders, Burkholderia pseudomallei infection, Campylobacter infection (campylobacteriosis), Campylobacteriosis, cancer (e.g. colorectal cancer (colon cancer), gynecological cancer, lung cancer, prostate cancer, skin cancer, etc.), Candida infection (candidiasis), Candida infection, canine influenza, Capillaria infection (capillariasis), Capillariasis, carbapenem-resistant Klebsiella pneumoniae (CRKP), cat flea tapeworm, cercarial dermatitis, cerebral palsy, cervical cancer, Chagas' Gass disease (Trypanosoma cruzi infection), varicella (varicella disease), chikungunya fever (CHIKV), childhood arthritis, German measles (Rubella virus), measles, mumps, rotavirus infection, chlamydia (Chlamydia trachomatis disease), Chlamydia pneumoniae infection, Chlamydia trachomatis disease, cholera (Vibrio cholerae infection), chronic fatigue syndrome (CFS), chronic obstructive pulmonary disease (COPD), ciguatera fish poisoning, ciguatera toxins, classic Creutzfeldt-Jakob disease, clonorchiasis, clonorchiasis infection (clonorchiasis), Clostridium botulinum, Clostridium difficile infection, Clostridium perfringens infection, Clostridium tetani infection, coagulopathy, CMV (cytomegalovirus infection), coal workers' pneumoconiosis, coccidioidomycosis, colorectal cancer (colon cancer),Common cold, conjunctivitis, Cooley's anemia, chronic obstructive pulmonary disease (COPD), Corynebacterium diphtheriae infection, Coxiella burnetii infection, Creutzfeldt-Jakob disease, CRKP (carbapenem-resistant Klebsiella pneumoniae), Crohn's disease, cryptococcosis, cryptosporidiosis, Cryptosporidium infection (cryptosporidiosis), Cyclospora infection (cyclosporiasis), Cyclosporiasis, Cysticercosis, Cystoisosporia infection (cystisosporiasis), Cystoisosporiasis, Cytomegalovirus infection (CMV), Dengue fever (DF), Dengue hemorrhagic fever (DHF), Dermatophytes, Skin diseases, Diabetes, Diamond fan anemia (DBA), Diminucleate amoeba fragilis infection, Diphtheria (diphtheria Corynebacterium infection), Diphyllobothrium infection, Diphyllobothrium infection (Diphyllobothrium infection), Dipylidium infection, Dog flea tapeworm, Down syndrome (Trisomy 21 syndrome), Guinea worm disease, Dwarf tapeworm (Hymenolepithecus infection), Escherichia coli infection (E. coli infection), Ear infection (otitis media), Eastern equine encephalitis (EEE), Ebola hemorrhagic fever, Hydatid disease, Ehrlichiosis, Elephantiasis, Encephalitis (mosquito- and tick-borne), Entamoeba histolytica infection, Pinworm infection, Enterovirus infection (non-poliomyelitis), Epidemic typhus, Epilepsy, Epstein-Barr virus infection (EBV infection), Escherichia coli infection, Extensively drug-resistant tuberculosis (XDR TB), Fasciola infection (fascioliasis), Fasciola infection (fascioliasis), Fibromyalgia, Fifth disease (Parvovirus B19 infection), Flavor-associated lung disease, Folliculitis, Food-related illness, Clostridium perfringens infection, Fragile X syndrome, Francisella tularensis infection, Genital Candida infection (vulvovaginal Candida infection (VVC)), Genital herpes (herpes simplex virus infection), Genital warts, German measles (Rubella virus), Giardia infection (Giardiasis), Glanders (Burkholderia mallei), Gnatostomatosis, Gnatostomatosis (Gnatostoma infection), Gonorrhea (Neisseria gonorrhoeae infection), Gout, Granulomatous amebic encephalitis (GAE), Group A Streptococcus infection (GAS) (Group A Streptococcus infection), Group B Streptococcus infection (GBS) (Group B Streptococcus infection), Medinalong Nematode disease (Dracunculiasis), gynecological cancers (such as cervical cancer, ovarian cancer, uterine cancer, vaginal and vulvar cancer, etc.), H1N1 influenza, Haemophilus influenzae infection (Hib infection), hand, foot and mouth disease (HFMD), leprosy, Hantavirus pulmonary syndrome (HPS), head lice (head lice), heart disease (cardiovascular health), heat stress, hemochromatosis, hemophilia, Hendra virus infection, herpes B virus, herpes simplex virus infection, Heterocystis infection (Heterocystis disease), Hib infection (Haemophilus influenzae infection), hypertension, capsular histoplasmosis, histoplasmosis (capsular histoplasmosis), hot tub rash (Pseudomonas dermatitis infection), HPV infection (human papillomavirus infection), human ehrlichiosis, human immunodeficiency virus, human papillomavirus infection (HPV infection), Hymenoleucella infection,Hypertension, Hyperthermia, Hypothermia, Impetigo, Infectious Mononucleosis, Inflammatory Bowel Disease (IBD), Influenza, Avian Flu, H1N1 Flu, Pandemic Flu, Seasonal Flu, Swine Flu, Invasive Candidiasis, Iron Overload (Hemochromatosis), Isospora Infection (Isospora), Japanese Encephalitis, Jaundice, Klebsiella Pneumoniae (Klebsiella Pneumoniae), Kala-Azar, Kawasaki Disease (KS), Kernicterus, Klebsiella Pneumoniae (Klebsiella Pneumoniae), La Crosse Encephalitis (LAC), La Crosse Encephalitis Virus (LACV), Lassa Fever, Latex Allergy, Lead Poisoning, Legionnaires' Disease (Legionellosis), Leishmania Infection (Leishmaniasis), Leprosy, Leptospira Infection (Leptospirosis), Leptospirosis, Leukemia lice, listeria infection (listeriosis), listeriosis, liver disease and hepatitis, loiasis, tetanus, Lou Gehrig's disease, lung cancer, lupus (SLE) (systemic lupus erythematosus), Lyme disease (Borrelia burgdorferi infection), lymphatic filariasis, lymphedema, lymphocytic choriomeningitis (LCMV), lymphogranuloma venereum infection (LGV), malaria, Marburg hemorrhagic fever, measles, melioidosis (Burkholderia pseudomallei infection), meningitis (meningococcal disease), meningococcal disease, methicillin-resistant Staphylococcus aureus (MRSA), micronutrient deficiencies, microsporidia infections, molluscum contagiosum, simian virus B, monkeypox, Morgellons disease, mosquito-borne diseases, mucormycosis, multidrug-resistant tuberculosis (MDR TB), mumps, Mycobacterium abscessus infection, Mycobacterium avium complex (MAC), Mycoplasma pneumoniae infection, myiasis, Naegleria melitensis infection (primary amebic meningoencephalitis (PAM)), necrotizing fasciitis, neglected tropical diseases (NTDs), Neisseria gonorrhoeae infection, neurocysticercosis, novel Creutzfeldt-Jakob disease, neonatal jaundice (kernicterus), Nipah virus encephalitis, nocardiosis, non-polio enterovirus infection, non-pathogenic (harmless) enteric protozoa, norovirus infection, Norwalk-like virus (NLV), novel H1N1 influenza, onchocerciasis, Clonorchis sinensis infection, oral cancer, oropharyngeal virus, oropharyngeal candidiasis (OPC), osteoarthritis (OA), osteoporosis, Otitis, ovarian cancer, pandemic influenza, paragonimiasis, paragonimiasis infection (paragonimiasis), parasitic diseases, parvovirus B19 infection, human head lice, human body lice, pelvic inflammatory disease (PID), peripheral arterial disease (PAD), whooping cough, tuberculosis, pink eye (conjunctivitis), pinworm infection (Enteroides vermiformis infection), plague (Yersinia pestis infection), Pneumocystis jiroveci pneumonia, pneumonia, poliomyelitis infection (poliomyelitis infection), Pontiac fever, prion disease (transmissible spongiform encephalopathy (TSE)), prostate cancer, Pseudomonas dermatitis infection, psittacosis, pubic lice (pediculosis), pulmonary hypertension, Q fever (Coxiella burnetii infection), rabies, raccoon roundworm infection (Baylis ascaris infection),Rat-bite fever (RBF) (Streptobacillus moniliformis infection), recreational water illness (RWI), relapsing fever, respiratory syncytial virus infection (RSV), rheumatoid arthritis (RA), rickettsial infections, Rift Valley fever (RVF), ringworm (dermatophytes), ringworm, river blindness (onchocerciasis), Rocky Mountain spotted fever (RMSF) (rickettsial infection), rotavirus infection, RVF (Rift Valley fever), RWI (recreational water illness), Salmonella infection (Salmonellosis), scabies, scarlet fever, schistosomiasis (schistosomiasis infection), seasonal influenza, severe acute respiratory syndrome, sexually transmitted diseases (STDs) (e.g. bacterial vaginosis (BV), chlamydia, genital herpes, gonorrhea, human papillomavirus infection, pelvic floor infection Acne, syphilis, trichomoniasis, HIV / AIDS, etc.), Shigella infection (shigellosis), herpes zoster (varicella zoster virus (VZV)), sickle cell disease, single gene disease, sinus infection (sinusitis), skin cancer, sleeping sickness (African trypanosomiasis), smallpox (smallpox major and minor), mouth ulcer infection (orthosis virus), southern tick-borne rash illness (STARI), spina bifida (myelomeningocele), sporotrichosis, spotted fever group rickettsial (SFGR), St. Louis encephalitis, Staphylococcus aureus infection, Streptococcus moniliformis infection, streptococcal disease, Streptococcus pneumoniae infection, stroke, strongyloidiasis infection (strongyloidiasis), sudden infant death syndrome (SIDS), swimmer's itch (cercarial dermatitis ), swine flu, syphilis (Treponema pallidum infection), systemic lupus erythematosus (SLE), tapeworm infection (tapeworm infection), testicular cancer, tetanus (Clostridium tetani infection), thrush (oropharyngeal candidiasis (OPC)), tick-borne relapsing fever, tick-borne diseases (e.g., anaplasmosis, babesiosis, ehrlichiosis, Lyme disease, Tourette syndrome (TS), toxic shock syndrome (TSS), toxocariasis (Toxocara infection), toxoplasmosis (Toxoplasma infection), trachoma infection, transmissible spongiform encephalopathy (TSE), traumatic brain injury (TBI), trichinosis (trichinosis), trichomoniasis (Trichomonas infection), tuberculosis (TB) (Mycobacterium tuberculosis infection), tularemia (Francisco tularensis infection), typhoid fever (Salmonella enterica serovar Typhimurium infection), uterine cancer, vaginal and vulvar cancer, vancomycin-neutralizing / resistant Staphylococcus aureus infection (VISA / VRSA), vancomycin-resistant Enterococcus infection (VRE), variant Creutzfeldt-Jakob disease (vCJD), varicella-zoster virus infection, major and minor smallpox, Vibrio cholerae infection, Vibrio parahaemolyticus infection, Vibrio vulnificus infection, viral gastroenteritis, viral hemorrhagic fever (VHF), viral hepatitis, viral meningitis (aseptic meningitis), von Willebrand disease, vulvovaginal candidiasis (VVC), West Nile virus infection, western equine encephalitis infection, whipworm infection (whipworm disease), Whittemore's disease, whooping cough, xenotropic murine leukemia virus-related virus infection, yellow fever,Yersinia pestis infection, Yersiniasis (enterocolitis Yersinia infection), zoonotic hookworm disease, zygomycosis, etc.

[0165] In some cases, therapeutic methods utilizing one or more sensor RNAs disclosed herein can be used to treat cancer. Cancers whose treatment may include the use of one or more proteolytically cleavable polypeptides disclosed herein will vary and may include, but are not limited to, for example, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, AIDS-related cancers (e.g., Kaposi's sarcoma, lymphoma, etc.), anal carcinoma, appendix cancer, astrocytoma, atypical teratoid / rhabdoid tumor, basal cell carcinoma, bile duct cancer (extrahepatic), bladder cancer, bone cancer (e.g., Ewing's sarcoma, osteosarcoma, and malignant fibrous histiocytoma, etc.), brain stem glioma, brain tumors (e.g., astrocytoma, central nervous system embryonic tumor, central nervous system germ cell tumor, craniopharyngioma, ependymoma, etc.), breast cancer (e.g., female Breast cancer (e.g., breast cancer in men, breast cancer in children, etc.), bronchial tumors, Burkitt's lymphoma, carcinoid tumors (e.g., children, gastrointestinal tract, etc.), cancer of unknown primary, cardiac tumors, central nervous system (e.g., atypical teratoid / rhabdoid tumors, embryonal tumors, germ cell tumors, lymphomas, etc.), cervical cancer, childhood cancer, chordoma, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myeloproliferative neoplasms, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, ductal (e.g., bile duct, extrahepatic, etc.), ductal carcinoma in situ (DCIS), embryonal tumors, endometrial cancer, ependymoma, esophageal cancer, neuroblastoma, Ewing's sarcoma, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, eye cancer (e.g. intraocular melanoma, retinoblastoma, etc.), bone fibrohistiocytoma (e.g. malignant osteosarcoma, etc.), gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors (GIST), germ cell tumors (e.g. extracranial, extragonadal, ovarian, testicular, etc.), gestational trophoblastic disease, glioma, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular carcinoma, histiocytosis (e.g. Langerhans cell, etc.), Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (e.g. pancreatic neuroendocrine tumors, etc.), Kaposi's sarcoma, kidney cancer (e.g. renal cell tumor, Wilms tumor, childhood kidney tumor, etc.), Langerhans cell group Histiocytosis, laryngeal cancer, leukemia (e.g. acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), hairy cell leukemia, etc.), lip cancer and oral cancer, liver cancer (primary), lobular carcinoma in situ (LCIS), lung cancer (e.g. non-small cell, small cell, etc.), lymphoma (e.g. AIDS-related lymphoma, Burkitt's lymphoma, cutaneous T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, primary central nervous system lymphoma (CNS), etc.), macroglobulinemia (e.g. Waldenstrom's lymphoma, etc.), male breast cancer, malignant fibrous histiocytoma of bone and osteosarcoma, melanoma,Merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, midline tract cancer involving the NUT gene, oral cancer, multiple endocrine neoplasms syndrome, multiple myeloma / plasma cell neoplasms, mycosis fungoides, myelodysplastic syndrome, myelodysplasia / myeloproliferative neoplasms, myeloid leukemia (e.g., chronic (CML) etc.), myeloid leukemia (e.g., acute (AML) etc.), myeloproliferative neoplasms (e.g., chronic nasal and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, oral cancer, oral cancer (e.g., lip cancer, etc.), oropharyngeal cancer, osteosarcoma and malignant fibrous histiocytoma of bone, ovarian cancer (e.g., epithelial, germ cell tumors, low malignant potential tumors, etc.), pancreatic cancer, pancreatic neuroendocrine tumors (islet cell tumors), papillomatosis, paraganglioma, paranasal sinus and nasal cancer, parathyroid cancer, penile cancer, pharyngeal cancer, Pheochromocytoma, pituitary tumor, pleuropulmonary blastoma, primary central nervous system (CNS) lymphoma, prostate cancer, colorectal cancer, renal cell (kidney) cancer, renal pelvis and ureter, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma (e.g., Ewing sarcoma, Kaposi sarcoma, osteosarcoma, rhabdomyosarcoma, soft tissue, uterine, etc.), Sézary syndrome, skin cancer (e.g., childhood skin cancer, melanoma, Merkel cell carcinoma) , non-melanoma, etc.), small cell lung cancer, small intestinal cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer (such as occult primary cancer, metastatic cancer, etc.), gastric cancer, T-cell lymphoma, testicular cancer, laryngeal cancer, thymoma and thymic cancer, thyroid cancer, renal pelvis and ureteral transitional cell carcinoma, ureter and renal pelvis cancer, urethral cancer, uterine cancer (such as endometrial cancer, etc.), uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, etc.

[0166] Composition

[0167] Compositions for practicing the methods of the present disclosure are also described. In general, the subject compositions may have a sensor RNA as described above in addition to a pharmaceutically acceptable excipient. In some embodiments, the subject compositions contain a secondary agent for treating any of the diseases or conditions described above.

[0168] The compositions of the present disclosure can be administered by any suitable means, including topical, oral, parenteral, intrapulmonary and intranasal. Parenteral infusion includes intramuscular, intravenous (bolus or slow drip), intraarterial, intraperitoneal, intrathecal or subcutaneous administration. The medicament can be administered in any medically acceptable manner. This can include injection, by parenteral routes, such as intravenous, intravascular, intraarterial, subcutaneous, intramuscular, intratumoral, intraperitoneal, intraventricular, epidural or other routes, as well as oral, nasal, ophthalmic, rectal or topical. The present disclosure also particularly includes sustained release administration, by means such as sustained release injection or erodible implants.

[0169] As described above, the sensor RNA can be formulated with a pharmaceutically acceptable carrier (one or more natural or synthetic organic or inorganic ingredients, combined with the subject agent to facilitate its use). Suitable carriers include sterile saline, although other aqueous and non-aqueous isotonic sterile solutions and sterile suspensions known to those skilled in the art are known to be pharmaceutically acceptable. An "effective amount" refers to an amount that can improve or delay the progression of a diseased, degenerative or damaged condition. The effective amount can be determined on an individual basis and is based in part on considerations of the symptoms to be treated and the results sought. Those skilled in the art can determine the effective amount using these factors and only routine experiments.

[0170] The composition can be administered in unit dosage form and can be prepared by any method well known in the art. Such methods include combining the medicament with a pharmaceutically acceptable carrier or diluent constituting one or more auxiliary components. A pharmaceutically acceptable carrier is selected according to the selected route of administration and standard pharmaceutical practice. Each carrier must be "pharmaceutically acceptable", i.e. compatible with the other ingredients in the formulation and not causing harm to the subject. The carrier can be solid or liquid, and the type is usually selected according to the type of administration used.

[0171] Depending on the individual and condition to be treated and the route of administration, the active agent may be administered at a dosage of 0.01 mg to 500 mg per kg of body weight per day, for example about 20 mg per day for an average person. The dosage of pediatric formulations will be appropriately adjusted.

[0172] In some embodiments, the composition is formulated in an aqueous buffer. Suitable aqueous buffers include, but are not limited to, acetate, succinate, citrate, and phosphate buffers, with strengths ranging from 5 mM to 100 mM. In some embodiments, the aqueous buffer includes an agent that provides an isotonic solution. Such agents include, but are not limited to, sodium chloride; and sugars, such as mannitol, glucose, sucrose, and the like. In some embodiments, the aqueous buffer also includes a nonionic surfactant, such as polysorbate 20 or 80. Optionally, the composition may also include a preservative. Suitable preservatives include, but are not limited to, benzyl alcohol, phenol, chlorobutanol, benzalkonium chloride, and the like. In many cases, the composition is stored at about 4°C. Pharmaceutical compositions may also be lyophilized, in which case they typically include antifreeze agents, such as sucrose, trehalose, lactose, maltose, mannitol, and the like. Lyophilized preparations may be stored for a long time even at ambient temperature.

[0173] The composition can be prepared as an injection, which can be a liquid solution or suspension; it can also be prepared in a solid form suitable for dissolution or suspension in a liquid vehicle before injection. As described above, the preparation can also be emulsified or encapsulated in liposomes or microparticles, such as polylactic acid, polyglycolic acid or copolymers, to enhance the adjuvant effect. Langer, Science 249:1527, 1990 and Hanes, Advanced Drug Delivery Reviews 28:97-119, 1997. The composition of the present invention can be administered in the form of a long-acting injection or implant, which can be formulated in a manner that allows for sustained or pulsatile release of the active ingredient. The pharmaceutical composition is typically formulated to be sterile, substantially isotonic, and fully comply with all good manufacturing practice (GMP) regulations of the U.S. Food and Drug Administration.

[0174] As described above, the composition may also include a secondary agent for treating any of the above-mentioned diseases or conditions. When the disease or condition is cancer, the secondary agent may be a chemotherapeutic agent. Chemotherapeutic agents that can be used in the present disclosure include, but are not limited to, abitterex (methotrexate injection), Abraxane (paclitaxel injection), Adcetris (brentuximab vedotin injection), doxorubicin (doxorubicin), Adrucil injection (5-FU (fluorouracil)), Afinitor (everolimus), Afinitor Disperz (everolimus), Alimta (PEMETEXED), Alkeran injection (melphalan injection), Alkeran tablets (melphalan), Aredia (pamidronate), Arimidex (Arimidex nastrazole), Aromasin (exemestane), Arranon (nelarabine), Arzerra (ofatumumab injection), Avastin (bevacizumab), Bexxar (tositumomab), BiCNU (carmustine), Blenoxane (bleomycin), Bosulif (bosutinib), Busulfex injection (busulfan injection), Campath (alemtuzumab), Camptosar (irinotecan), Caprelsa (vandetanib), Casodex (bicalutamide), CeeNU (lomustine), Dose Pack (lomustine), Cerubidine (daunorubicin), Clolar (clofarabine injection), Cometriq (cabozantinib), Cosmegen (actinomycin D), CytosarU (cytarabine), Cytoxan (cyclophosphamide injection), Cytoxan injection (cyclophosphamide injection), Dacogen (decitabine), DaunoXome (daunorubicin lipid complex injection), Decadron (dexamethasone), DepoCyt (cytarabine lipid complex injection), Dexamethasone Intensol (dexamethasone), DexpakTaperpak (dexamethasone), Docefrez (docetaxel), Doxil (doxorubicin lipid complex injection), Droxia (hydroxyurea), DTIC (decarbazine), Eligard (leuprorelin), Ellence (epirubicin), Eloxatin (oxaliplatin), Elspar (asparaginase), Emcyt (estramustine), Erbitux (cetuximab), Erivedge (vismodegib), Erwinaze (asparaginase Erwinia chrysanthemi), Ethyol (amifostine), Etopophos (etoposide injection), Eulexin (flutamide), Fareston (toremifene), Faslode x (fulvestrant), Femara (letrozole), Firmagon (degarelix injection), Fludara (fludarabine), Folex (methotrexate injection), Folotyn (pralatrexate injection), FUDR (fluridine), Gemzar (gemcitabine), Gilotrif (afatinib), Gleevec (imatinib mesylate), Gliadel Wafer (carmustine wafer), Halaven (eribulin injection), Herceptin (trastuzumab), Hexalen (hexamethylmelamine), Hycamtin (topotecan), Hydrea (hydroxyurea), lclusig (ponatinib), Idamycin PFS (idarubicin), Ifex (ifosfamide), Inlyta (axitinib), Intron A alfab (interferon alfa-2a), Iressa (gefitinib), Istodax (romidepsin injection), Ixempra (ixabepilone injection), Jakafi (ruxolitinib), Jevtana (cabazitaxel injection), Kadcyla (enmedadol trastuzumab), Kyprolis (carfilzomib), Leukeran (chlorambucil), Leukine (sargramostim), Leustatin (cladribine), Lupron (leuprolide), Lupron Depot (leuprolide), Lupron DepotPED (leuprolide), Lysodren (mitotane), MarqiboKit (vincristine lipid complex injection), Matulane (procarbazine), Megace (megestrol acetate), Mekinist (trametinib), Mesnex (mesna), Mesnex (mesna injection), Metastron (strontium-89 chloride), Mexate (methotrexate injection), Mustargen (nitrogen mustard), Mutamycin (mitomycin), Myleran (busulfan), Mylotarg (gemtuzumab ozogamicin), Navelbine (vinorelbine), Neosar injection (cyclophosphamide injection), Neulasta (filgrastim), Neulasta (pegfilgrastim), Neupogen (filgrastim), Nexa Var (sorafenib), Nilandron (nilutamide), Nipent (pentostatin), Nolvadex (tamoxifen), Novantrone (mitoxantrone), Oncaspar (pegaspargase), Oncovin (vincristine), Ontak (denileukin), Onxol (paclitaxel injection), Panretin (alitretin), Paraplatin (carboplatin), Perjeta (pertuzumab injection), Platinol (cisplatin), Platinol AQ (cisplatin), Pomalyst (pomalidomide), Prednisone Intensol (prednisone), Proleukin (aldesleukin), Purinethol (mercaptopurine), Reclast (zoledronic acid), Revlimid (lenalidomide), Rheumatrex (methotrexate), Rituxan (rituximab), RoferonA alfaa (interferon alfa-2a), Rubex (doxorubicin), Sandostatin (octreotide), Sandostatin LAR Depot (octreotide), Soltamox (tamoxifen), Sprycel (dasatinib), Sterapred (prednisone), Sterapred DS (prednisone), Stivarga (regorafenib), SupprelinLA (histrelin implant), Sutent (sunitinib), Sylatron (pegylated interferon alfa-2b injection (Sylatron)), Synribo (omacitabine injection), Tabloid (thioguanine), Taflinar (dabrafenib), Tarceva (erlotinib), Targretin capsules (bexarotene), Tasigna (dacarbazine), Taxol (paclitaxel injection), Taxotere (docetaxel), Temodar (temozolomide), Tepadina (thiotepa), Thalomid (thalidomide), TheraCys BCG (BCG), Thioplex (thiotepa), TICEBCG (BCG), Toposar (etoposide injection), Torisel (temsirolimus), Treanda (bendamustine hydrochloride), Trelstar (triptorelin injection), Trexall (methotrexate), Trisenox (arsenic trioxide), Tykerb (lapatinib), Valstar (valrubicin intravesical injection), Vantas (histrelin implant), Vectibix (panitumumab), Velban (vinblastine), Velcade (bortezomib), Vepesid (etoposide), Vepesid (etoposide injection), Vesanoid (retinoic acid), Vidaza (azacitidine), Vincasar PFS (vincristine), Vincrex (vincristine), Votrient (pazopanib), Vumon (teniposide), Wellcovorin IV (leucovorin injection), Xalkori (crizotinib), Xeloda (capecitabine), Xtandi (enzalutamide), Yervoy (ipilimumab injection), Zaltrap (Ziv-aflibercept injection), Zanosar (streptozotocin), Zelboraf (vemurafenib), Zevalin (ibrutinib tiuxetan), Zoladex (goserelin), Zolinza (vorinostatin), he, Zometa (zoledronic acid), Zortress (everolimus), Zytiga (abiraterone), nimotuzumab, and immune checkpoint inhibitors such as nivolumab, pembrolizumab / MK-3475, pilitumumab, and AMP-224 for PD-1; and BMS-935559, MEDI4736, MPDL3280A, and MSB0010718C for PD-L1, and drugs targeting CTLA-4 such as ipilimumab.

[0175] When the disease or condition is associated with infection, the secondary agent can be an antibiotic. The antibiotics used in the present disclosure include, but are not limited to, aminoglycoside antibiotics; carbapenem antibiotics; etc.; penicillins, such as penicillin G, penicillin V, methicillin, oxacillin, carbenicillin, nafcillin, ampicillin, etc.; a combination of penicillin and a β-lactamase inhibitor; cephalosporins, such as cefaclor, cefazolin, cefuroxime, mosartan, etc.; tetracyclines; cephalosporins; quinolones; lincomycins; macrolides; sulfonamides; glycopeptides, including anti-infective antibiotics vancomycin, teicoplanin, telavancin, ramoplanin, and decatalin. Vancomycin derivatives include, for example, oritavancin and dalbavancin (both lipoglycopeptides). Telavancin is a semi-synthetic lipoglycopeptide derivative of vancomycin (approved by FDA in 2009). Other vancomycin analogs are disclosed in, for example, WO2015022335A1 and Chen et al. (2003) PNAS 100 (10): 5658-5663, each of which is specifically incorporated herein by reference. Non-limiting examples of antibiotics include vancomycin, linezolid, azithromycin, daptomycin, colistin, eperzolid, fusidic acid, rifampicin, tetracycline, fidaxomicin, clindamycin, lincomycin, rifalazil and clarithromycin.

[0176] Reagent test kit

[0177] Also provided are kits for implementing the methods described in the present disclosure. In general, the subject kit may include a sensor RNA as described above. The sensor RNA may be contained in a lipid nanoparticle, or the sensor RNA may be located in a recombinant vector as described above. In some cases, the kit also includes an ADAR protein or its coding sequence. When the kit includes an ADAR coding sequence, it may be located in a recombinant vector as described above. When the kit includes an ADAR protein or its coding sequence, the ADAR protein may be any of the above-mentioned ADAR proteins.

[0178] In some cases, the kit may further comprise positive and / or negative controls. A positive control may be in the form of a biological sample containing a target RNA, i.e., a sensor RNA containing an edited codon (i.e., a stop codon edited to a non-stop codon, or a start codon edited to a non-start codon, or a non-start codon edited to a start codon) or a sensor RNA containing a target RNA nucleotide sequence. A negative control may be a sample containing no target RNA.

[0179] The subject kit may include any combination of components for implementing the disclosed method. The components of the subject kit may exist as a mixture, or may be a separate entity. In some cases, the components exist in the form of a lyophilized mixture. In some cases, the components exist in the form of a liquid mixture. The components of the subject kit may be located in identical or separate containers, and may exist in any combination.

[0180] The subject kit may also include (in certain embodiments) instructions for implementing the subject method. These instructions may be present in the subject kit in various forms, wherein one or more forms may be present in the kit. These instructions may be present in a suitable medium or substrate in the form of printed information, such as one or more sheets of printed information, in the kit packaging, in the package instructions, etc. Another form of these instructions is a computer readable medium, such as a floppy disk, an optical disc (CD), a flash drive, etc., wherein information is recorded. Another form of these instructions is a website address, the information of a remote site can be accessed through the Internet.

[0181] Example

[0182] The following examples are presented to provide one of ordinary skill in the art with a complete disclosure and description of how to make and use the invention, but are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent that the experiments below are all or the only experiments performed. Every effort has been made to ensure the accuracy of the numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is degrees Celsius, and pressure is at or near atmospheric pressure. Standard abbreviations may be used, for example, bp, base pairs; kb, kilobase; pl, picoliter; s or sec, seconds; min, minutes; h or hr, hours; aa, amino acids; nt, nucleotides; im, intramuscular (ly); ip, intraperitoneal (ly); sc, subcutaneous (ly); and the like.

[0183] Example 1

[0184] The RADAR sensor is inspired by recent advances in the field of RNA editing (Katrekar, D. et al. (2019) Nat. Methods 16, 239-242; Qu, L. et al. (2019) Nat. Biotechnol. 37, 1059-1069; Merkle, T. et al. (2019) Nat. Biotechnol. 37, 133-138; Reautschnig, P. et al. (2022) Nat. Biotechnol. 1-10), and consists of three parts (Figure 1a): a marker coding sequence; a sensor sequence that is reverse complementary to the target RNA of interest ("trigger" or "target"), but has an editing-enhancing C:A mismatch at the central UAG stop codon (alternative pairing can be used); and an output coding sequence. The stop codon prevents translation of the output CDS so that only the marker (e.g., mCherry) is expressed. In the presence of a trigger, double-stranded RNA (dsRNA) is formed, which recruits ADARs to edit adenosine (A) in UAG to inosine (I), thereby enabling translation of downstream CDS (e.g., EGFP). The "self-cleaving" 2A sequence (Loughran, G. et al. (2017) RNA NYN 23, 1285-1289) isolates the flanking CDS from the variable sensing sequence. We first focused our efforts on the 3' untranslated region (UTR) to find trigger sequences because, compared to trigger sequences in CDS, they do not encounter translating ribosomes that may affect or be affected by dsRNA, and any changes in the 3'UTR due to unintentional ADAR editing are unlikely to lead to harmful results. Most human (57%) and mouse (73%) genes have a 90bp trigger candidate sequence with at least one reported 3'UTR variant.

[0185] The de novo designed trigger T1 (embedded in the 3'UTR of the co-transfected gene) validated RADAR in human embryonic kidney (HEK) cells (Figure 1b). The corresponding sensor S1 output was ADAR-dependent and was most enhanced by the p150 isoform of ADAR1 (Figure 1b, Figure 3d-g). We determined that the S1 output was strongly correlated with the T1 plasmid input, approximately a linear function over two orders of magnitude (Figure 1c). The RADAR output is modular because we can use Cre recombinase (a useful tool in neurobiology) (Luo, L. et al. (2018) Neuron 98, 256-281) as an alternative output (Figure 1d).

[0186] We then validated RADAR in scenarios closer to our final use case. First, in addition to a transiently delivered trigger plasmid, we saw an increase in output in response to doxycycline-induced expression of T1 embedded in the 3’UTR of genomically integrated EGFP (Fig. 1e). EGFP levels were not negatively affected by the presence of S1 (Fig. 4e). Second, to test whether our design functions in the complex context of a native 3’UTR, we engineered the sensor SBdnf for a subsequence within the 2.9 kb 3’UTR of murine Bdnf, explicitly testing using mouse-human orthogonality. We observed a significant response of SBdnf to the Bdnf 3’UTR expressed in HEK cells (Fig. 1f). Finally, we investigated the 3’UTR sensor for DNAJB1, a member of the hsp40 family of heat shock response proteins. While the T1 sensor was unaffected, sDNAJB1 output was significantly increased upon heat shock (Fig. 1g), suggesting that sDNAJB1 specifically senses endogenous DNAJB1 expression. We further evaluated the GAPDH sensor and showed how the sensor could detect changes in GAPDH levels after siRNA knockdown (Fig. 1g).

[0187] We then explored strategies to expand coverage of the human / mouse transcriptome. First, using the 3'UTR of Bdnf, we observed that RADAR performance remained largely unchanged with 72bp dsRNA (Figure 1h). Second, inspired by studies showing that ADAR enzymes tolerate or even benefit from disruption of target dsRNA (Uzonyi, A. et al. (2021) Mol. Cell), we validated that we could rescue signaling from a nonfunctional 36bp sensor if we introduced an additional 54bp sequence complementary to another part of the long Bdnf 3'UTR, constituting a "split" design (Figure 1i). This split design provides great flexibility for multiple scenarios: skipping unwanted reverse-complement stop codons, skipping complex secondary structures, miRNA binding sites, or other functional features of the trigger RNA, distinguishing homologs that share CCA-containing sequences but have unique regions elsewhere, and detecting gene fusions and spliced ​​transcripts whose unique junctions are not suitable for direct sensing (no CCA near the junction). Finally, we validated that the CDS sensor of EGFP (SEGFP) exhibited a significant response to trigger induction (Figure 1j), although not as ideal as the 3'UTR sensor (Figure 4d-f), providing an alternative if necessary but also reaffirming our initial priority for the 3'UTR.

[0188] Combining the ability to shorten the sensor, adopt a split design, and sense CDS, >85% of human (Fig. 1k, Fig. 4g) and mouse (Fig. 4h) genes have at least one candidate trigger sequence that is compatible with RADAR.

[0189] Although ADAR overexpression greatly improves the dynamic range of RADAR, it may produce harmful side effects. To improve this potential problem, we used an engineered version of ADAR that contains only the mutant deaminase domain of ADAR2 and the MS2 RNA binding protein MCP ("ADAR (DD) -MCP") (Katrekar, D. et al. (2019) Nat. Methods 16, 239-242; Biswas, J. et al. (2020) iScience 23, 101318). Combining this enzyme with a sensor with MS2, we achieved a dynamic range similar to that of ADAR1p150 overexpression (Figure 1l). Crucially, ADAR (DD) -MCP does not affect the original sensor lacking MS2 (Figure 1l), indicating that this "orthogonal" ADAR is unlikely to edit endogenous dsRNA structures.

[0190] RADAR has a variety of unique functions and potential applications. For example, RADAR can be used for cell classification (Figure 2a). RADAR can also integrate multiple inputs using OR and logic (Figure 2b, 2c); for the latter, two sensor sequences can be directly connected so that both stop codons must be edited for output expression.

[0191] Cell states, especially in medical contexts, are often defined not only by the expression level of RNA, but also by the presence of new RNA sequences. We exploit the unique capabilities of RADAR to sense the latter. First, because ADAR is sensitive to the identity of bases around edited adenosine (Qu, L. et al. (2019) Nat. Biotechnol. 37, 1059-1069), RADAR is particularly suitable for distinguishing certain short genetic variants. As a demonstration, we validated sensors that distinguish two common TP53 oncogenic mutations associated with different invasive traits in cancer cells (Yoshikawa, K. et al. (2010) Biomed. Res. 31, 401-411) (Figure 2d) as well as single-base distinguishers (Figure 2d). About 5% of known or likely pathogenic variants reported in ClinVar can be distinguished from their wild-type alleles using RADAR. Second, since gene fusions drive many cancers (Gao, Q. et al. (2018) Cell Rep. 23, 227-238.e3), split designs provide a way to sense such fusions. We confirmed that the sensor was more responsive to split trigger sequences present on the same transcript than to the same trigger sequences on different transcripts (Figure 4i), indicating that fusion-specific sensors are feasible.

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202] Table 2 Variant pairs with an on / off ratio of 10 shown in Figure 2d

[0203] Finally, to demonstrate that RADAR is an independent module, we evaluated RADAR in plants (an organism lacking endogenous ADARs). Without any optimization other than switching to a plant promoter and vector, we observed an increase in fluorescence output in response to a matched T1 trigger compared to a mismatched trigger in the N. benthamiana model system (Fig. 2e), indicating that RADAR still functions as expected in a heterologous environment and is therefore likely applicable to a variety of species, even those lacking native ADAR machinery.

[0204] Here, we demonstrate the use of ADAR editing to create a modular, programmable molecular device that can sense multiple RNAs. A key direction for future improvements in RADAR is to increase input sensitivity (Figure 4a-c) to accommodate the expression levels of more endogenous RNAs. Designing new sensors is straightforward due to base pairing rules; plasmids encoding new sensors can be generated using standard techniques within two days of receiving short oligonucleotides. Since all RADAR components can be delivered via mRNA, various existing RNA synthetic biology tools (Dykstra, PB et al. (2022) Nat. Rev. Genet. 1-14) and advances in RNA nanotechnology (Groves, B. et al. (2016) Nat. Nanotechnol. 11, 287-294) can be combined with RADAR to produce cell classifiers, research tools, and smart dynamic therapies. For example, RADAR sensors can be used to track the process of cells transforming from normal cells to precancerous cells, cancerous cells, metastatic cells or aging after viral infection to study these processes, create smart therapies that can dynamically detect these state changes, and stop or even reverse the processes driving these changes. By integrating multiple inputs, RADAR can achieve high specificity and low off-target effects for downstream interventions. It is particularly suitable for improving the specificity of RNA-based vaccination and gene therapy, and its efficacy has been fully demonstrated during the recent epidemic. Because RADAR can be delivered by viruses or other genetic vectors and achieve cell type-specific expression, there is no need for promoter recognition, which has been a major obstacle to using new organisms for bioengineering or genetics-driven research.

[0205] The methods herein have a variety of applications. RADAR can be used for feedback gene editing, where once a desired mutation is detected, the gene editing enzyme can be turned off to reduce off-target editing. RADAR can be used for feedback gene expression in gene therapy, where transcription factors can be produced in response to the genes it regulates (either positively or negatively). This enables precise control of the expression level of the gene. RADAR can be used for marker-free cell therapy screening, where cells must be edited / designed with high fidelity, but this is often difficult to achieve without a selection marker (which is undesirable in most cases). RADAR can be used to temporarily select cells with the intended effect. RADAR can be used to detect plant pathogens, such as viruses. RADAR can be used to deliver oncolytics and anti-aging agents to kill diseased cells. RADAR can be used to manipulate cells based on their type or state: for example, sensing markers of T cell exhaustion and then modifying T cell therapy behavior; detecting whether a cell is the right dendritic cell expressing the antigen for a "tolerogenic vaccine" (some dendritic cells express antigens that make the body tolerant to them, so this is an allergy treatment). RADARs could be used to regulate engineered RNA viruses (e.g., alphaviruses and rabies viruses have been engineered for a variety of purposes, including therapies like self-amplifying RNA vaccines or cancer treatments, and our system could be used to control these purposes, such as regulating dosage and lifespan through negative feedback). Our system could be part of an RNA virus package or a separate co-delivery module. RADARs could be used as a safety device rather than feedback for engineered viruses; for example, one might not want to express an RNA-based therapeutic in a cell infected with a retrovirus like HIV, so our system could detect the presence of HIV RNA and shut it down so that the RNA does not integrate into the genome. (Of course, it could also attempt to deliver therapeutics / inhibitors to latent HIV). RADARs could also be used to screen eggs for the presence of certain mutations (non-destructive, non-modifying) before fertilization in IVF.

[0206] method

[0207] Plasmid generation. Plasmids were generated using standard molecular cloning methods, including InFusion of linearized plasmids and PCR fragments and restriction ligation of linearized fragments and annealed phosphorylated oligonucleotides. A complete list of plasmids and associated maps can be found in Table 3. Plasmids are available from the corresponding author upon request and will be deposited in Addgene. Human ADAR plasmids as well as the ADAR1 knockout cell line were generously provided by Professor Billy Li. Cre and Cre reporter plasmids were kindly provided by Professor Liqun Luo. pUBC_stdMCP_serinemod_E488QADAR_p2A_yGFP (“ADAR(DD)-MCP”) was a gift from Robert Singer (Addgene plasmid #154787;).

[0208]

[0209]

[0210]

[0211]

[0212] Table 3. List of plasmids used

[0213] Tissue culture. Flp-In T-REx human embryonic kidney (HEK) 293 cells were purchased from Thermo Scientific (Cat. No. R78007). Cells were cultured in Dulbecco's modified Eagle medium in a humidity-controlled incubator under standard culture conditions (37°C, 5% CO2), supplemented with 10% fetal bovine serum (Fisher Scientific Catalog No. FB12999102), 1 mM sodium pyruvate (EMD Millipore Catalog No. TMS-005-C), 1 x penicillin-streptomycin (Genesee Catalog No. 25-512), 2 mM L-glutamine (Genesee Catalog No. 25-509) and 1 x MEM non-essential amino acids (Genesee Catalog No. 25-536). In order to induce the expression of some constructs, 100 ng / mL doxycycline was added during transfection. Cell lines containing inducible triggers were generated by transfecting constructs in the PiggyBac backbone along with the PiggyBac integrase (4:1) and selected by adding 50 ug / mL hygromycin when replated in 10 cm dishes two days after transfection.

[0214] Transient transfection. HEK 293 cells were cultured in 24-well or 96-well tissue culture treated plates under standard culture conditions. When the cell confluence reached 70-90%, the plasmid constructs were transiently transfected into the cells using jetOPTIMUSR DNA transfection reagent (Polyplus catalog number 117-15) according to the manufacturer's instructions, using 0.375uL of reagent per 50uL jetOPTIMUS buffer in 24-well plates to transfect 500ng of total DNA, and 0.13uL of reagent per 12.5uL buffer in 96-well plates to transfect 130ng of total DNA. All transfection conditions are detailed in Table 4.

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225]

[0226]

[0227]

[0228]

[0229]

[0230] Table 4. Transfections performed. 24-well format: Approximately 100,000 cells were seeded. 50uL jetOptimus buffer per condition containing 0.375uL jetOptimus reagent was used for transfection the next day. Total DNA per condition was 500ng, the remainder was adjusted with filler plasmid. 96-well format: Approximately 25,000 cells were seeded. 12.5uL jetOptimus buffer per condition containing 0.13uL jetOptimus reagent was used for transfection the next day. Total DNA per condition was 130ng, the remainder was adjusted with filler plasmid. Plant infiltration: Agrobacterium was electroporated with each plasmid separately. Overnight inocula were verified by colony PCR. Cultures were diluted to an OD of 0.9 and mixed in equal amounts for infiltration.

[0231] Flow cytometry and data analysis. Cells were harvested by trypsinization approximately 48 hours after transfection and resuspended in flow buffer (HBSS + 2.5 mg / mL bovine serum albumin). After 40 μm filtration, cells were analyzed by flow cytometry (Biorad ZE5 cell analyzer) and data were processed using the cytoflow Python package. An overview of gating and analysis is given in Figures 3a and 3b.

[0232] RNA extraction and reverse transcription. HEK293T cells grown in 24-well plates were centrifuged and RNA was extracted using the following kits: RNAasy Mini Kit (Qiagen), RNase-free DNase Set (Qiagen), and QIAshredder (Qiagen). After extraction, RNA quality was assessed by running 500 ng on a 1% agarose gel. 500 ng of purified RNA was then reverse transcribed using iScript cDNA synthesis (Biorad). For Sanger sequencing, cDNA was sent to Genewiez / Azenta along with matching primers.

[0233] qPCR measurement. qPCR was performed on QuantStudio3 (Applied Biosystems) using SYBR-Green. RNA estimates were calculated based on the calibration curve of the purified plasmid and normalized by the Ct threshold. The following primer pair sequences for GFP (Signagen) and the standardization gene (β-actin) were used: GFP-F AAGCAGAAGAACGGCATCAA (SEQ ID NO: 10), GFP-r TCCAGCAGGACCATGTGATC (SEQ ID NO: 11), β-actin-FCGTCCACCGCAAATGCTT (SEQ ID NO: 12), β-actin-R GTTTTCTGCGCAAGTTAGGTTTTGT (SEQ ID NO: 13).

[0234] Leaf infiltration and analysis. Three leaves of three Nicotiana benthamiana plants were infiltrated with Agrobacterium transformed with RADAR components (sensor and human ADAR1p150) and matched or irrelevant triggers, respectively, with two infiltrations per leaf. Quantification was based on the average of the mean fluorescence intensity of six rectangular areas per infiltration point. EGFP (output) fluorescence was normalized using mCherry (marker) fluorescence intensity.

[0235] Statistical analysis. The values ​​reported are the mean of at least three biological replicates and represent two independent biological experiments. For experiments comparing two groups, significance was assessed using a two-tailed Student's t-test with a Bonferroni correction.

[0236] Bioinformatics. We analyzed all genes with annotated 3'UTRs in the human genome to find trigger sequences compatible with RADAR design. Later, we also considered all genes with CDS annotations. 3'UTR and CDS sequences were obtained from Ensembl Biomart. Candidate sequences had to have a 5'CCA 3' sequence (paired with 5'UAG 3' in the sensor) flanked by sufficiently long sequence segments; the reverse complement of the trigger sequence should not create an in-frame stop codon in the sensor. In addition, the trigger sequence should be unique (assessed by mapping to the genome) and the sensor sequence should be easy to synthesize (lack of homopolymer runs and GC content of 35-80%). The hg38 genome build was used for human transcriptome analysis and the GRCm39 build was used for mouse transcriptome analysis. The blastn tool version 2.9.0+ was used with the -task blastn -evalue 1 parameter, and further filtering was performed on alignment length (minimum 30 matches) and position (must overlap with central CCA or alternative sequences). Results from alternative chromosomes of repeated nature were removed. A single hit-target sequence was allowed, and sensors with more hits were discarded from the analysis; this meant that some designs were discarded due to pseudogenes and other repetitive regions that may or may not be expressed as RNA. Since sequences other than UAG:CCA pairs can be efficiently edited, we also analyzed candidate trigger sequences with central GCA, UCA, or CAA sequences.

[0237] The 20211025 version of ClinVar was used to analyze the potential for detecting known and likely pathogenic variants, assuming that UAG can be edited when paired with one of CAA, CUA, CGA, ACA, UCA, GCA, CCA, CCU, CCC (Qu, L. et al. (2019) Nat. Biotechnol. 37, 1059-1069). Based on the hg38 reference genome, alternative alleles and reference alleles were filled in by filling in one base on each side. If the filled alternative allele contains one of the variants that trigger editing, but the filled reference gene does not contain any variants, RADAR considers the variant to be distinguishable.

[0238] Example 2

[0239] Standard RADAR

[0240] In vitro transcribed mRNA and pseudouridine incorporation. Although the RADAR design does not require special modifications (ie, mRNA can be made by cells from DNA plasmids or in vitro using standard nucleotides), there are some circumstances where modifications may be impeded.

[0241] One such modification is pseudouridine (Ψ), specifically N1-methyl-pseudouridine, which is used in the synthesis of mRNA to reduce its immunogenicity. Typically, all uridine (U) bases in IVT mRNA are replaced with pseudouridine by providing a modified nucleoside triphosphate instead of UTP in the reaction. However, Ψ has a negative impact on ADAR editing. Furthermore, it increases readthrough of stop codons and is therefore particularly detrimental to RADARs - the off state looks less "off" due to the increased readthrough, and the on state looks less "on" due to the reduced editing.

[0242] If a UAG stop codon is used, ΨAG may be particularly affected in terms of editing because base stacking between Ψ and A is increased, preventing the necessary flipping of the A base. A UGA stop codon, especially when followed by a G (UGAg), may help in this context because ΨGAg does not place the modified base directly next to the A, although a 5'G will also reduce editing of the A. In addition to affecting the catalytic part of ADAR editing, Ψ may also affect the dsRNA binding ability of ADARs.

[0243] To generate IVT mRNA, a sensor or trigger plasmid containing a T7 promoter, TEV 5' leader UTR, and hybrid 3' UTR was amplified, and a 120 base polyA tail was added. The PCR amplicon was purified and used as a template for IVT reactions with CleanCap AG reagent, ATP, GTP, CTP, and T7 polymerase in the presence of mouse RNase inhibitor; the amount of UTP to N1mΨ was varied from 0-100%. IVT mRNA fidelity was verified on gel, DNA was removed with DNaseI, and mRNA was purified using the QIAgen RNeasy Mini Kit. mRNA was transfected using the TransIT-mRNA Kit with 500 ng of total mRNA per well in a 24-well plate, and flow cytometry was performed 20 hours later. ADAR was not overexpressed in the mRNA experiments, relying only on wild-type expression levels of ADAR1 in HEK293 cells. The trigger was located in the 3'UTR of BFP and a control sequence was used in the "no input" case, so that both conditions received 200 ng sensor and 300 ng BFP mRNA (with either matching or mismatching trigger sequence).

[0244] Complete pseudouridine incorporation did significantly reduce sensor function, but did not completely eliminate it, both by increasing baseline and reducing trigger-dependent activation ( Figure 8 and 10 ). However, satisfactory performance can be achieved using moderate levels of random pseudouridine incorporation.

[0245] UAG:NNN analysis. To understand nucleotide variant detection capabilities (single- and multi-nucleotide variants, SNVs and MNVs), all 5'NNN 3' trigger sequences relative to the UAG stop codon were probed.

[0246] The triggering abilities of the 64 5'NNN 3' sequences differed by about two logs ( Fig.10 and 11 ). A 64×64 matrix of NNN-NNN pairs can be compared, one in the “off” state and the other in the “on” state. The output fluorescence levels should be different enough to distinguish between the two states. The difference in the on-off activation ratio is characterized ( Fig.12 Many of the 4,096 NNN-NNN pairs can be distinguished by high on-off ratios ( Figure 6 Specifically, many of the 576 NNN-NNN pairs that differed at only one position (and were therefore SNVs) could also be distinguished using the on-off ratio ( Fig.13 ).

[0247] Effect of the bulge near UAG / CCA. Mismatches near the CCA:UAG pairing on the triggering strand were inserted. None of the tested mismatches, either 5' or 3', had a strong effect on sensor performance ( Fig.15 ).

[0248] ModulADAR / “Biased RADAR”

[0249] Previously known as "biased RADAR," this mechanism takes a canonical RADAR and uncouples RNA binding from RNA editing.

[0250] The sensor consists of: (1) a UAG / UGA / UAA stop codon within a stem-loop surrounded by sequences complementary to the trigger RNA, (2) a 2A tag, and (3) an output protein. An optional marker +2A tag can precede the sensor RNA.

[0251] Mechanism: Sensors and triggers form dsRNA around a stem-loop, which recruits ADARs. ADARs are then able to edit the stop codon within the stem-loop and remove it, allowing downstream output to be translated.

[0252] The stem-loop can be selected from naturally occurring ADAR editing sites or from library screening. Crucially, the stem-loop should not be edited without forming an extended dsRNA. For natural sites, this means that the stem-loop should be shortened, otherwise it will be edited by the ADAR without forming a dsRNA. The stem-loop is usually located in the middle of the sequence complementary to the trigger RNA, but this position can vary (e.g., 5' to the complementary region, 3' to the complementary region, or somewhere in between; it should be near the complementary region).

[0253] A key aspect is that the editing substrate is a stem-loop formed by the sensor, rather than a sensor:trigger dsRNA duplex—this is key to its novelty, as such a design has not been envisioned in International Application PCT / US2022 / 033459 or Qian et al. Nature 2022.

[0254] Portions of natural ADAR editing substrate stem-loops have been previously incorporated into guide RNAs for editing endogenous RNAs (rather than editing exogenous RNAs, such as the sensor RNAs described herein), e.g., Fukuda et al., Scientific Reports 2017. However, the stem-loops in these examples had been truncated to include the portion of the stem-loop that interacted with the ADAR dsRNA binding domain, whereas here, the stem-loop was truncated to the portion that interacted with and was edited by the ADAR catalytic domain. Other types of stem-loops that are not targets for ADAR editing have also been introduced into other guide RNAs with the goal of recruiting engineered ADAR enzymes to edit endogenous RNAs; these stem-loops include MS2 hairpins for recruiting MCP-ADAR (DD) (e.g., Azad et al. Gen eTherapy 2017 and International Application PCT / US2022 / 033459), or Cas13 binding hairpins for recruiting dCas13b-ADAR (DD) (e.g., Cox et al. Science 2017 and WO2019071048). However, in those applications, the stem-loop does not serve as an editing substrate containing an editable codon as here, but is used to recruit the engineered ADAR, whereas in ModulADAR, the dsRNA formed by the sensor and trigger RNAs recruits the natural ADAR.

[0255] A major advantage of varying the editing substrate is that this allows deep optimization of editing, independent of binding. ADAR enzymes have a dsRNA binding domain with little substrate specificity and a separate catalytic deaminase domain that does have some substrate preference. In the standard RADAR setup, the sensor dsRNA surrounding the editing site is determined by the sequence of the trigger RNA, so optimization of ADAR binding and editing is done together; here the choice is free. In the standard setup, the UAG stop codon was chosen because it is the most robust, especially if immediately paired with CCA; in the ModulADAR design, other stop codons can be utilized, which may be advantageous, for example because the UAA stop codon generally allows less readthrough than UAG, or because UGA (especially if followed by G, i.e. UGAG) may be less affected by uridine modification than UAG, because in the former the A is not surrounded by modified bases, while in the latter the A is surrounded (the commonly used pseudouridine modification inhibits ADAR editing).

[0256] Another advantage and novelty is that now more sequences can be selected as candidate triggers; in the standard design, every sequence should have CCA (or some few alternatives) that can base pair with UAG to edit it efficiently, while here there is no such requirement.

[0257] In principle, this approach (separating ADAR binding and editing) can also be applied to the "uORF", "AUA" and "AUG" approaches described in this disclosure. Priority is given to a list of natural editing targets with suitable motifs that can be used in each case. By placing the editing substrates in a separate, independent and trigger-independent sequence, motifs three bases larger than the stop codon can be used, for example, a strong Kozak sequence can be included before the non-start (AUA) or start codon (AUG) without the need to find the reverse complement of such a sequence in the trigger RNA, which would need to be found if editing occurs in the duplex formed by the sensor and trigger RNA.

[0258] Stem-loop selection. The selection of a stem-loop containing a stop codon is critical. When the ADAR is targeted by dsRNA formation, it should be well edited, but if there is no additional dsRNA formed by the sensor and trigger, no editing should occur.

[0259] One source of stem-loops are natural editing sites, which are often located in stem-loops. These stem-loops usually have stems long enough to bind to the dsRNA binding domain of the ADAR enzyme. For use in ModulADAR, the stem should be shortened to only the part that binds to the ADAR catalytic domain.

[0260] Natural editing sites often contain a UAG sequence; the stem-loop should be inserted into the sensor so that the UAG is in frame with the coding sequence. Natural editing sites also exist that contain UGA or UAA. For sequences containing UAA, both As should be naturally edited. Any other in-frame stop codons should be removed; they may be retained if they are also efficiently edited after ADAR colocalization.

[0261] Natural editing sites in the human genome have been catalogued (Gabay et al., Nature Communications 2022). A few of these sites have been tested; specifically, sites originating from the GLURB, CAPS1, GLI1, GABRA3, and HT2RC genes.

[0262] Generate stem-loops in the library and evaluate their performance. Based on the existing structure, the contact area of ​​the ADAR2 deaminase domain is approximately 12 bp, so the stems tested in this way should be approximately 9-30 bp, and the size of the stem refers to the base-paired portion of the stem-loop.

[0263] result

[0264] Basic properties. ModulADAR design works well when the stem-loop derived from GLURB (aka GLUR2, GRIA2) is located in the middle of the complementary region ( Fig.17 By exploring other natural editing sites located within the sensor nucleotide sequence in genes including CAPS1, GLI1, and GABRA3 ( Fig. 27 and Fig.28 ), further improvements were made. Very long stem-loops that incorporate most of the natural editing site may not perform as well as truncated stem-loops, such as stem-loop variant #4 (intact GLI1) vs. stem-loop variant #5 (truncated GLI1), with the loss of performance attributed to an increase in trigger-independent signaling ( Fig.28 ), which is to be expected, as the intact editing site should be well edited by ADARs even without additional dsRNAs, as it contains a stem long enough to recruit ADARs. By shortening the stem, editing depends on the dsRNA formed by the sensor and trigger, as envisioned by the ModulADAR design. A similar trend, albeit smaller, was observed for the two variants derived from GABRA3, with the longer stem-loop variant #6 showing a higher baseline ( Fig.28 Importantly, the conditions in which the trigger was present were similar in these comparisons, again supporting a mechanism whereby the dsRNA formed by the sensor and trigger (which were identical in these comparisons) recruits the ADARs, which then edit the substrate, which is part of the stem-loop. Changing the stop codon in the GLURB-derived stem-loop to UAA performed poorly ( Fig.28), probably because two adenosines need to be edited; adding an additional mismatch, so that two adenosines in the UAA codon are opposite cytosines, did not improve performance. Natural sites with UAA sequences, such as those occurring in HT2RC, can be used. The CAPS1 gene contains a natural editing site with a UGA subsequence, which was used here to evaluate the third stop codon option ( Fig.28 ).

[0265] OR logic. OR logic in the standard case (no editable stem-loop) is achieved by co-delivering two independent RNAs with different inputs. This means that if there are two inputs, A and B, the output dose from "A" alone will be about 50%, the output dose from "B" alone will be about 50%, and the output dose from "A" and "B" together will be 100%.

[0266] The ModulADAR technique can be used to make single-molecule OR gates such that the output for all cases (“A” only, “B” only, or “A” and “B” together) will be roughly the same ( Fig.25 ). This is another aspect of novelty, as this is not possible when editing occurs in a dsRNA duplex, requiring the use of two different molecules as described above.

[0267] uORF RADAR

[0268] The sensor consists of: (1) AUG surrounded by sequences complementary to the trigger RNA, and (2) output (with AUG). The first AUG is severely mismatched with the output AUG, making the first reading frame act as an "upstream open reading frame" to inhibit translation starting from the output AUG start codon.

[0269] Mechanism: During dsRNA formation, the first AUG is set to be edited into IUG; IUG (GUG) is no longer a start codon and closes the upstream reading frame, allowing the downstream frame to be translated.

[0270] Ideally, the upstream reading frame is long, almost as long as the correct downstream reading frame. There should not be any other AUGs within the sensor sequence.

[0271] Two uORFs can be placed in series to form an AND gate (both inputs must be present to remove both uORFs).

[0272] result

[0273] The uORF mechanism works best when ADAR2 is overexpressed ( Fig.18 ). The uORF mechanism reached about 29% of the positive control level ( Fig.19The uORF machinery output was greatly improved by removing the stop codon in frame with the uORF from the exported protein, thus allowing the uORF to generate a long reading frame ( Fig. 20 ). Two uORFs in series can form an AND gate.

[0274] AUG RADAR

[0275] This design is derived from the “uORF” design, but instead of editing the upstream reading frame, it directly edits the AUG of the output reading frame.

[0276] The sensor consists of: (1) AUG start codon surrounded by sequences complementary to the trigger RNA, (2) 2A tag, and (3) output. All components are in the same frame with each other.

[0277] Mechanism: During dsRNA formation, AUG is set to be edited to IUG; IUG (GUG) is no longer a start codon, thereby preventing the translation of the exported protein.

[0278] Here, the output turns off in response to the input ("NOT X" type logic), which is the opposite of all other designs where the output turns on in response to the input.

[0279] There should not be any in-frame AUG sequences within the sensor that would allow functional production of the exported protein. The sensor should not have an in-frame stop codon downstream of the AUG.

[0280] AUG RADAR is similar to uORF RADAR, except that there is no second downstream reading frame; the "upstream" reading frame contains the desired output.

[0281] result

[0282] Basic features. The AUG mechanism works with cytoplasmic trigger mRNA (i.e., canonical mRNA).

[0283] AUA RADAR

[0284] The sensor consists of: (1) AUA surrounded by sequences complementary to the trigger RNA, (2) 2A tag, and (3) output (no AUG). All components are in frame with each other.

[0285] Mechanism: After dsRNA formation, AUA is programmed to edit into AUI; AUI(AUG) can act as a start codon and enable translation of the otherwise untranslated export protein.

[0286] There should not be any in-frame AUG sequences within the sensor that would allow functional production of the exported protein. The sensor should not have an in-frame stop codon downstream of the AUA.

[0287] It helps to have a separate, long, overlapping reading frame in a different frame from the main frame; this stabilizes the RNA when it is in the "off" state.

[0288] When two AUA sensors are connected in series, OR logic can be implemented on a single RNA strand (as opposed to two RNAs in the standard RADAR design).

[0289] result

[0290] Basic characterization. The AUA mechanism works best when ADAR2 is overexpressed ( Fig.24 ).

[0291] combination

[0292] Different types can be combined together to achieve different logic functions. Below RADAR are standard RADAR or ModulADAR types.

[0293]

[0294]

[0295] Table 4. Sensor architecture combinations

[0296] References

[0297] 1. Kulkarni, A., Anderson, AG, Merullo, DP & Konopka, G. Curr. Opin. Biotechnol. 58, 129-136 (2019).

[0298] 2.Xie, Z., Liu, SJ, Bleris, L. & Benenson, Y. Nucleic Acids Res. 38, 2692-2701 (2010).

[0299] 3.Xie, Z., Wroblewska, L., Prochazka, L., Weiss, R. & Benenson, Y. Science 333, 1307-1311 (2011).

[0300] 4.Han,S.et al.Mol.Ther.-Nucleic Acids 27,797-809(2022).

[0301] 5.Ying,Z.-M.,Wang,F.,Chu,X.,Yu,R.-Q.&Jiang,J.-H.Angew.Chem.Int.Ed.59,18599-18604(2020).

[0302] 6.Lin,J.,Wang,W.-J.,Wang,Y.,Liu,Y.&Xu,LJAm.Chem.Soc.143,19834-19843(2021).

[0303] 7.Hochrein,LM,Li,H.&Pierce,NAACS Synth.Biol.(2021).doi:10.1021 / acssynbio.1c00037

[0304] 8.Zhao,EMet al.Nat.Biotechnol.1-7(2021).doi:10.1038 / s41587-021-01068-2

[0305] 9.Hur,S.Annu.Rev.Immunol.37,349-375(2019).

[0306] 10.Gatsiou,A.,Vlachogiannis,N.,Lunella,FF,Sachse,M.&Stellos,K.Antioxid.Redox Signal.29,846-863(2017).

[0307] 11.Goodman,RA,Macbeth,MR&Beal,PAAdenosine Deaminases Act.RNAADARs--Ed.1-33(2012).doi:10.1007 / 82_2011_144

[0308] 12.Gallo,A.,Vukic,D.,Michalik,D.,O'Connell,MA&Keegan,LPHum.Genet.136,1265-1278(2017).

[0309] 13.Wang,Y.,Zheng,Y.&Beal,PAThe Enzymes 41,215-268(2017).

[0310] 14.Katrekar,D.et al.Nat.Methods 16,239-242(2019).

[0311] 15.Qu,L.et al.Nat.Biotechnol.37,1059-1069(2019).

[0312] 16.Merkle,T.et al.Nat.Biotechnol.37,133-138(2019).

[0313] 17.Reautschnig,P.et al.Nat.Biotechnol.1-10(2022).doi:10.1038 / s41587-021-01105-0

[0314] 18.Loughran,G.,Howard,M.T.,Firth,A.E.&Atkins,J.F.RNA N.Y.N 23,1285-1289(2017).

[0315] 19.Luo,L.,Callaway,E.M.&Svoboda,K.Neuron 98,256-281(2018).

[0316] 20.Uzonyi,A.et al.Mol.Cell(2021).doi:10.1016 / j.molcel.2021.03.024

[0317] 21.Biswas,J.,Rahman,R.,Gupta,V.,Rosbash,M.&Singer,R.H.iScience 23,101318(2020).

[0318] 22.Yoshikawa,K.et al.Biomed.Res.31,401-411(2010).

[0319] 23.Gao,Q.et al.Cell Rep.23,227-238.e3(2018).

[0320] 24.Dykstra,P.B.,Kaplan,M.&Smolke,C.D.Nat.Rev.Genet.1-14(2022).doi:10.1038 / s41576-021-00436-7

[0321] 25. Groves, B. et al. Nat. Nanotechnol. 11, 287-294 (2016).

[0322] Notwithstanding the appended claims, the disclosure set forth herein is also described by the following items:

[0323] 1. A method for detecting a target RNA in a biological sample, the method comprising:

[0324] (a) combining the biological sample with a sensor RNA comprising:

[0325] (i) a first nucleotide sequence comprising a stem-loop sequence containing one or more stop codons,

[0326] (ii) a second nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the target RNA,

[0327] (iii) a third nucleotide sequence encoding a first cleavage domain, and

[0328] (iv) a fourth nucleotide sequence encoding an exported protein; and

[0329] (b) determining the presence of the exported protein in the biological sample.

[0330] 2. The method according to item 1, wherein the one or more stop codons comprise at least one base mismatch with a sequence within the stem loop relative to the one or more stop codons.

[0331] 3. The method according to item 1 or 2, further comprising:

[0332] (i) a fifth nucleotide sequence comprising a second cleavage domain, wherein the fifth nucleotide sequence is located before the first nucleotide sequence, and

[0333] (ii) a sixth nucleotide sequence comprising a nucleotide sequence encoding a marker protein, wherein the sixth nucleotide sequence is located before the fifth nucleotide sequence.

[0334] 4. The method according to any one of items 1 to 3, wherein the cleavage domain is a 2A self-cleavage domain.

[0335] 5. The method according to item 4, wherein the 2A self-cleavage domain is selected from T2A, P2A, E2A and F2A.

[0336] 6. The method according to any one of items 1 to 5, wherein the stem-loop is a GluR-B stem-loop or a modified variant thereof.

[0337] 7. The method according to any one of items 1 to 6, wherein the stem-loop has a length of 18 to 60 base pairs.

[0338] 8. The method according to any one of items 1 to 7, wherein the sensor nucleotide sequence has a length of 60 nucleotides or more.

[0339] 9. The method according to any one of items 1 to 8, wherein the target RNA is encoded by a gene fusion, a splice variant or a gene variant comprising a single nucleotide polymorphism.

[0340] 10. The method according to any one of items 1 to 9, wherein the sensor nucleotide is reverse complementary to the 3'UTR of the target RNA.

[0341] 11. The method according to any one of items 1 to 10, wherein the marker protein is a fluorescent protein or a luminescent protein.

[0342] 12. The method according to any one of items 1 to 11, wherein the exported protein is selected from the group consisting of a fluorescent protein, a genome modification protein, a transcription factor, a killer factor, a toxin, an antigen, a T cell receptor, a therapeutic protein and an enzyme.

[0343] 13. The method according to any one of items 1 to 12, wherein the detection is quantitative or qualitative.

[0344] 14. The method according to any one of items 1 to 13, wherein the biological sample is a cell.

[0345] 15. The method according to any one of items 1 to 14, wherein the combining with a biological sample comprises contacting the biological sample with a lipid nanoparticle comprising the sensor RNA or an adeno-associated virus (AAV) comprising the sensor RNA, wherein the sensor RNA is contained in an AAV vector.

[0346] 16. The method according to any one of items 1 to 14, wherein said combining with a biological sample comprises transfecting said biological sample with a recombinant vector comprising said sensor RNA.

[0347] 17. The method according to item 16, wherein the recombinant vector is selected from the group consisting of a plasmid, a viral vector, a cosmid and an artificial chromosome.

[0348] 18. The method according to any one of items 1 to 17, wherein determining the presence of the exported protein comprises using immunoblotting.

[0349] 19. The method according to any one of items 1 to 17, wherein determining the presence of the exported protein comprises using microscopy.

[0350] 20. The method according to any one of items 1 to 17, wherein determining the presence of the exported protein comprises using flow cytometry.

[0351] 21. The method according to any one of items 1 to 20, wherein the sensor RNA comprises one or more MS2 hairpins.

[0352] 22. The method according to any one of items 1 to 21, wherein the sensor nucleotide sequence is reverse complementary to two or more discontinuous sequences within a single target RNA.

[0353] 23. The method according to any one of items 1 to 22, wherein the sensor nucleotide sequence is reverse complementary to two or more different target RNAs.

[0354] 24. The method according to any one of items 1 to 23, wherein the sensor RNA further comprises a nucleotide sequence encoding a second sensor nucleotide sequence that is reverse complementary to a second target RNA, wherein the sequences of the first target RNA and the second target RNA are different.

[0355] 25. The method according to item 24, wherein the second sensor nucleotide sequence comprises a second stop codon.

[0356] 26. The method according to item 24, wherein the second sensor nucleotide sequence comprises a stem-loop sequence of one or more stop codons or start codons.

[0357] 27. The method according to any one of items 1 to 26, further comprising combining the biological sample with an adenosine deaminase acting on RNA (ADAR) protein or a coding sequence thereof.

[0358] 28. The method according to item 27, wherein the ADAR protein is ADAR2, ADAR p110 or ADAR p150 .

[0359] 29. The method according to item 27, wherein the ADAR protein is a modified ADAR comprising an ADAR deaminase domain and an MS2 binding domain.

[0360] 30. The method according to any one of items 1 to 29, wherein the biological sample is combined with two or more sensor RNAs, which detect two or more target RNAs.

[0361] 31. The method according to any one of items 1 to 20, wherein the sensor RNA comprises one or more pseudouridines.

[0362] 32. The method according to item 31, wherein 75% or less of the uridine in the sensor RNA is pseudouridine.

[0363] 33. The method according to any one of items 31-32, wherein the pseudouridine is N1-methyl-pseudouridine.

[0364] 34. The method according to any one of items 1 to 33, wherein the stop codon is UGA.

[0365] 35. The method according to item 34, wherein adenylate in the UGA stop codon is followed by guanosine.

[0366] 36. The method according to any one of items 31 to 35, wherein the pseudouridine is not adjacent to an adenylate in the stop codon of the sensor nucleotide sequence.

[0367] 37. A method for detecting a target RNA in a biological sample, the method comprising:

[0368] (a) combining the biological sample with a sensor RNA comprising:

[0369] (i) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to a target RNA, wherein the sensor nucleotide sequence comprises a stem-loop sequence containing one or more stop codons,

[0370] (ii) a second nucleotide sequence encoding a first cleavage domain, and

[0371] (iii) a third nucleotide sequence encoding an exported protein; and

[0372] (b) determining the presence of the exported protein in the biological sample.

[0373] 38. The method according to item 37, further comprising:

[0374] (i) a fourth nucleotide sequence comprising a second cleavage domain, wherein the fourth nucleotide sequence is located before the first nucleotide sequence, and

[0375] (ii) a fifth nucleotide sequence comprising a nucleotide sequence encoding a marker protein, wherein the fifth nucleotide sequence is located before the fourth nucleotide sequence.

[0376] 39. The method according to items 37-38, wherein the one or more stop codons comprise at least 1 base mismatch with the sequence within the stem loop opposite to the one or more stop codons.

[0377] 40. Method according to any of items 37-39, wherein the cleavage domain is a 2A self-cleavage domain.

[0378] 41. The method according to item 40, wherein the 2A self-cleavage domain is selected from T2A, P2A, E2A and F2A.

[0379] 42. The method according to any one of items 37 to 41, wherein the stem-loop is a GluR-B stem-loop or a modified variant thereof.

[0380] 43. The method according to any one of items 37 to 42, wherein the stem-loop has a length of 9 to 24 base pairs.

[0381] 44. The method according to any one of items 37 to 43, wherein the sensor nucleotide sequence is 60 or more nucleotides in length.

[0382] 45. The method according to any one of items 37 to 44, wherein the target RNA is encoded by a gene fusion, a splice variant or a gene variant comprising a single nucleotide polymorphism.

[0383] 46. ​​The method according to any one of items 37 to 45, wherein the sensor nucleotide is reverse complementary to the 3'UTR of the target RNA.

[0384] 47. The method according to any one of items 37 to 46, wherein the marker protein is a fluorescent protein or a luminescent protein.

[0385] 48. The method according to any one of items 37 to 47, wherein the exported protein is selected from the group consisting of a fluorescent protein, a genome modification protein, a transcription factor, a killer factor, a toxin, an antigen, a T cell receptor, a therapeutic protein and an enzyme.

[0386] 49. The method according to any one of items 37-48, wherein said detecting is quantitative or qualitative.

[0387] 50. The method according to any one of items 37 to 49, wherein the biological sample is a cell.

[0388] 51. A method according to any one of items 37-50, wherein the combining with a biological sample comprises contacting the biological sample with a lipid nanoparticle comprising the sensor RNA or an adeno-associated virus (AAV) comprising the sensor RNA, wherein the sensor RNA is contained in an AAV vector.

[0389] 52. The method according to any one of items 37 to 51, wherein said combining with a biological sample comprises transfecting said biological sample with a recombinant vector comprising said sensor RNA.

[0390] 53. The method according to item 52, wherein the recombinant vector is selected from the group consisting of a plasmid, a viral vector, a cosmid and an artificial chromosome.

[0391] 54. The method according to any one of items 37-53, wherein determining the presence of the exported protein comprises using immunoblotting.

[0392] 55. The method according to any one of items 37-54, wherein determining the presence of the exported protein comprises using microscopy.

[0393] 56. The method according to any one of items 37-55, wherein determining the presence of the exported protein comprises using flow cytometry.

[0394] 57. The method according to any one of items 37 to 56, wherein the sensor RNA comprises one or more MS2 hairpins.

[0395] 58. The method according to any one of items 37 to 57, wherein the sensor nucleotide sequence is reverse complementary to two or more discontinuous sequences within a single target RNA.

[0396] 59. The method according to any one of items 37-58, wherein the sensor nucleotide sequence is reverse complementary to two or more different target RNAs.

[0397] 60. The method according to any one of items 37 to 59, wherein the sensor RNA further comprises a nucleotide sequence encoding a second sensor nucleotide sequence that is reverse complementary to a second target RNA, wherein the sequences of the first target RNA and the second target RNA are different.

[0398] 61. The method according to item 60, wherein the second sensor nucleotide sequence comprises a second stop codon or a first start codon.

[0399] 62. The method according to item 60, wherein the second sensor nucleotide sequence comprises a stem-loop sequence of one or more stop codons or start codons.

[0400] 63. The method according to any one of items 37 to 62, further comprising combining the biological sample with an adenosine deaminase acting on RNA (ADAR) protein or a coding sequence thereof.

[0401] 64. The method according to item 63, wherein the ADAR protein is ADAR2 or ADAR p150 .

[0402] 65. The method according to item 63, wherein the ADAR protein is a modified ADAR comprising an ADAR deaminase domain and an MS2 binding domain.

[0403] 66. The method according to any one of items 37 to 65, wherein the biological sample is combined with two or more sensor RNAs that detect two or more target RNAs.

[0404] 67. The method according to any one of items 37 to 66, wherein the sensor RNA comprises one or more pseudouridines.

[0405] 68. The method according to item 67, wherein 75% or less of the uridine in the sensor RNA is pseudouridine.

[0406] 69. The method according to any one of items 37 to 68, wherein the pseudouridine is N1-methyl-pseudouridine.

[0407] 70. The method according to any one of items 37-69, wherein the stop codon is UGA.

[0408] 71. The method according to item 70, wherein adenylate in the UGA stop codon is followed by guanosine.

[0409] 72. The method according to any one of items 67 to 71, wherein the pseudouridine is not adjacent to an adenylate in the stop codon of the sensor nucleotide sequence.

[0410] 73. A method for detecting a target RNA in a biological sample, the method comprising:

[0411] (a) combining the biological sample with a sensor RNA comprising:

[0412] (i) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the 3'UTR of the target RNA, wherein the sensor nucleotide sequence comprises one or more stop codons,

[0413] (ii) a second nucleotide sequence encoding a first cleavage domain, and

[0414] (iii) a third nucleotide sequence encoding an exported protein; and

[0415] (b) determining the presence of the exported protein in the biological sample.

[0416] 74. The method according to item 73, further comprising:

[0417] (i) a fourth nucleotide sequence comprising a second cleavage domain, wherein the fourth nucleotide sequence is located before the first nucleotide sequence, and

[0418] (ii) a fifth nucleotide sequence comprising a nucleotide sequence encoding a marker protein, wherein the fifth nucleotide sequence is located before the fourth nucleotide sequence.

[0419] 75. The method according to any one of items 73-74, wherein the one or more stop codons comprise at least 1 base mismatch with the 3'UTR of the target mRNA sequence.

[0420] 76. Method according to any of items 73 to 75, wherein the cleavage domain is a 2A self-cleavage domain.

[0421] 77. The method according to item 76, wherein the 2A self-cleavage domain is selected from T2A, P2A, E2A and F2A.

[0422] 78. The method according to any of items 73 to 77, further comprising a fifth nucleotide sequence comprising a second cleavage domain, wherein the fifth nucleotide sequence is located before the second nucleotide sequence.

[0423] 79. The method according to any one of items 73 to 78, wherein the sensor nucleotide sequence is 60 or more nucleotides in length.

[0424] 80. The method according to any one of items 73 to 79, wherein the target RNA is encoded by a gene fusion, a splice variant or a gene variant comprising a single nucleotide polymorphism.

[0425] 81. The method according to any one of items 73 to 80, wherein the marker protein is a fluorescent protein or a luminescent protein.

[0426] 82. The method according to any one of items 73 to 81, wherein the exported protein is selected from the group consisting of a fluorescent protein, a genome modification protein, a transcription factor, a killer factor, a toxin, an antigen, a T cell receptor, a therapeutic protein and an enzyme.

[0427] 83. The method according to any one of items 73 to 82, wherein said detecting is quantitative or qualitative.

[0428] 84. The method according to any one of items 73 to 83, wherein the biological sample is a cell.

[0429] 85. The method according to any one of items 73-84, wherein the combining with the biological sample comprises contacting the biological sample with a lipid nanoparticle comprising the sensor RNA or an adeno-associated virus (AAV) comprising the sensor RNA, wherein the sensor RNA is contained in an AAV vector.

[0430] 86. The method according to any one of items 73 to 85, wherein said combining with a biological sample comprises transfecting said biological sample with a recombinant vector comprising said sensor RNA.

[0431] 87. The method according to item 86, wherein the recombinant vector is selected from the group consisting of a plasmid, a viral vector, a cosmid and an artificial chromosome.

[0432] 88. The method according to any one of items 73-87, wherein determining the presence of the exported protein comprises using immunoblotting.

[0433] 89. The method according to any one of items 73-88, wherein determining the presence of the exported protein comprises using microscopy.

[0434] 90. The method according to any one of items 73-89, wherein determining the presence of the exported protein comprises using flow cytometry.

[0435] 91. The method according to any one of items 73 to 90, wherein the sensor RNA comprises one or more MS2 hairpins.

[0436] 92. The method according to any one of items 73 to 91, wherein the sensor nucleotide sequence is reverse complementary to two or more discontinuous sequences within a single target RNA.

[0437] 93. The method according to any one of items 73 to 92, wherein the sensor nucleotide sequence is reverse complementary to two or more different target RNAs.

[0438] 94. The method according to any one of items 73 to 93, wherein the sensor RNA further comprises a nucleotide sequence encoding a second sensor nucleotide sequence that is reverse complementary to a second target RNA, wherein the sequences of the first target RNA and the second target RNA are different.

[0439] 95. The method according to item 94, wherein the second sensor nucleotide sequence comprises a second stop codon or a first start codon.

[0440] 96. The method according to item 94, wherein the second sensor nucleotide sequence comprises a stem-loop sequence of one or more stop codons or start codons.

[0441] 97. The method according to any one of items 73 to 96, further comprising combining the biological sample with an adenosine deaminase acting on RNA (ADAR) protein or a coding sequence thereof.

[0442] 98. The method according to item 97, wherein the ADAR protein is ADAR2 or ADAR p150 .

[0443] 99. The method according to item 98, wherein the ADAR protein is a modified ADAR comprising an ADAR deaminase domain and an MS2 binding domain.

[0444] 100. The method according to any one of items 73-99, wherein the biological sample is combined with two or more sensor RNAs, which detect two or more target RNAs.

[0445] 101. The method according to any one of items 73 to 100, wherein the sensor RNA comprises one or more pseudouridines.

[0446] 102. The method according to item 101, wherein 75% or less of the uridine in the sensor RNA is pseudouridine.

[0447] 103. The method according to any one of items 101-102, wherein the pseudouridine is N1-methyl-pseudouridine.

[0448] 104. The method according to any one of items 73 to 103, wherein the stop codon is UGA.

[0449] 105. The method according to item 104, wherein adenylate in the UGA stop codon is followed by guanosine.

[0450] 106. The method according to any one of items 104-105, wherein the pseudouridine is not adjacent to an adenylate in the stop codon of the sensor nucleotide sequence.

[0451] 107. A method for detecting a target RNA in a biological sample, the method comprising:

[0452] (a) combining the biological sample with a sensor RNA comprising:

[0453] (i) a first nucleotide sequence comprising a sensor nucleotide sequence complementary to the target RNA, wherein the sensor nucleotide sequence comprises a start codon, and

[0454] (iii) a second nucleotide sequence encoding an exported protein; and

[0455] (b) determining the presence of the exported protein in the biological sample.

[0456] 108. The method according to item 107, wherein said sequence encoding said export protein comprises a start codon.

[0457] 109. The method according to any one of items 107-108, wherein the start codon in the sensor sequence comprises at least 1 base mismatch with a target RNA sequence.

[0458] 110. The method according to any of items 107-109, further comprising:

[0459] (i) a third nucleotide sequence comprising a first cleavage domain, wherein the third nucleotide sequence is located between the first nucleotide sequence and the second nucleotide sequence.

[0460] 112. The method according to any one of items 107 to 110, wherein the sensor nucleotide sequence is 70 or more nucleotides in length.

[0461] 113. The method according to any one of items 107 to 112, wherein the target RNA is encoded by a gene fusion, a splice variant or a gene variant comprising a single nucleotide polymorphism.

[0462] 114. The method according to any one of items 107 to 113, wherein the exported protein is selected from the group consisting of a fluorescent protein, a genome modification protein, a transcription factor, a killer factor, a toxin, an antigen, a T cell receptor, a therapeutic protein and an enzyme.

[0463] 115. The method according to any of items 107-114, wherein said detecting is quantitative or qualitative.

[0464] 116. The method according to any one of items 107 to 115, wherein the biological sample is a cell.

[0465] 117. The method according to any one of items 107-116, wherein the combining with the biological sample comprises contacting the biological sample with a lipid nanoparticle comprising the sensor RNA or an adeno-associated virus (AAV) comprising the sensor RNA, wherein the sensor RNA is contained in an AAV vector.

[0466] 118. The method according to any one of items 107 to 117, wherein said combining with a biological sample comprises transfecting said biological sample with a recombinant vector comprising said sensor RNA.

[0467] 119. The method according to item 118, wherein the recombinant vector is selected from the group consisting of a plasmid, a viral vector, a cosmid and an artificial chromosome.

[0468] 120. The method according to any one of items 107-119, wherein determining the presence of the exported protein comprises using immunoblotting.

[0469] 121. The method according to any one of items 107-120, wherein determining the presence of the exported protein comprises using microscopy.

[0470] 122. The method according to any one of items 107-121, wherein determining the presence of the exported protein comprises using flow cytometry.

[0471] 123. The method according to any one of items 107 to 122, wherein the sensor RNA comprises one or more MS2 hairpins.

[0472] 124. The method according to any one of items 107 to 123, wherein the sensor nucleotide sequence is reverse complementary to two or more discontinuous sequences within a single target RNA.

[0473] 125. The method according to any one of items 107 to 124, wherein the sensor nucleotide sequence is reverse complementary to two or more different target RNAs.

[0474] 126. The method according to any one of items 107 to 125, wherein the sensor RNA further comprises a nucleotide sequence encoding a second sensor nucleotide sequence that is reverse complementary to a second target RNA, wherein the sequences of the first target RNA and the second target RNA are different.

[0475] 127. The method according to item 126, wherein the second sensor nucleotide sequence comprises a second stop codon or a first start codon.

[0476] 128. The method according to item 126, wherein the second sensor nucleotide sequence comprises a stem-loop sequence of one or more stop codons or start codons.

[0477] 129. The method according to any one of items 107-128, further comprising combining the biological sample with an adenosine deaminase acting on RNA (ADAR) protein or a coding sequence thereof.

[0478] 130. The method according to item 129, wherein the ADAR protein is ADAR2 or ADAR p150 .

[0479] 131. The method according to item 130, wherein the ADAR protein is a modified ADAR comprising an ADAR deaminase domain and an MS2 binding domain.

[0480] 132. The method according to any one of items 107-131, wherein the biological sample is combined with two or more sensor RNAs, which detect two or more target RNAs.

[0481] 133. A method for detecting a target RNA in a biological sample, the method comprising:

[0482] (a) combining the biological sample with a sensor RNA comprising:

[0483] (i) a first nucleotide sequence comprising a sensor nucleotide sequence complementary to the target RNA, wherein the sensor nucleotide sequence comprises an AUA sequence, and

[0484] (iii) a second nucleotide sequence encoding an exported protein; and

[0485] (b) determining the presence of the exported protein in the biological sample.

[0486] 134. The method according to item 133, wherein the AUA sequence comprises at least 1 base mismatch with the target RNA sequence.

[0487] 135. The method according to any of items 133-134, further comprising:

[0488] (i) a third nucleotide sequence comprising a first cleavage domain, wherein the third nucleotide sequence is located between the first nucleotide sequence and the second nucleotide sequence.

[0489] 137. The method according to any of items 133 to 135, wherein the sensor nucleotide sequence is 70 or more nucleotides in length.

[0490] 138. The method according to any one of items 133 to 137, wherein the target RNA is encoded by a gene fusion, a splice variant or a gene variant comprising a single nucleotide polymorphism.

[0491] 139. The method according to any one of items 133 to 138, wherein the exported protein is selected from the group consisting of a fluorescent protein, a genome modification protein, a transcription factor, a killer factor, a toxin, an antigen, a T cell receptor, a therapeutic protein and an enzyme.

[0492] 140. The method according to any of items 133 to 139, wherein said detecting is quantitative or qualitative.

[0493] 141. The method according to any one of items 133 to 140, wherein the biological sample is a cell.

[0494] 142. The method according to any one of items 133 to 141, wherein the combining with a biological sample comprises contacting the biological sample with a lipid nanoparticle comprising the sensor RNA or an adeno-associated virus (AAV) comprising the sensor RNA, wherein the sensor RNA is contained in an AAV vector.

[0495] 143. The method according to any one of items 133 to 142, wherein said combining with a biological sample comprises transfecting said biological sample with a recombinant vector comprising said sensor RNA.

[0496] 144. The method according to item 143, wherein said recombinant vector is selected from the group consisting of a plasmid, a viral vector, a cosmid and an artificial chromosome.

[0497] 145. The method according to any one of items 133-144, wherein determining the presence of the exported protein comprises using immunoblotting.

[0498] 146. The method according to any one of items 133 to 145, wherein determining the presence of the exported protein comprises using microscopy.

[0499] 147. The method according to any one of items 133 to 146, wherein determining the presence of the exported protein comprises using flow cytometry.

[0500] 148. The method according to any of items 133 to 147, wherein the sensor RNA comprises one or more MS2 hairpins.

[0501] 149. The method according to any one of items 133 to 148, wherein the sensor nucleotide sequence is reverse complementary to two or more discontinuous sequences within a single target RNA.

[0502] 150. The method according to any one of items 133 to 149, wherein the sensor nucleotide sequence is reverse complementary to two or more different target RNAs.

[0503] 151. The method according to any one of items 133 to 150, wherein the sensor RNA further comprises a nucleotide sequence encoding a second sensor nucleotide sequence that is reverse complementary to a second target RNA, the first target RNA and the second target RNA having different sequences.

[0504] 152. The method according to item 151, wherein the second sensor nucleotide sequence comprises a stop codon or a start codon.

[0505] 153. The method according to item 151, wherein the second sensor nucleotide sequence comprises a stem-loop sequence of one or more stop codons or start codons.

[0506] 154. The method according to any one of items 133 to 153, further comprising combining the biological sample with an adenosine deaminase acting on RNA (ADAR) protein or a coding sequence thereof.

[0507] 155. The method according to item 154, wherein the ADAR protein is ADAR2 or ADAR p150 .

[0508] 156. The method according to item 155, wherein the ADAR protein is a modified ADAR comprising an ADAR deaminase domain and an MS2 binding domain.

[0509] 157. The method according to any one of items 133 to 156, wherein the biological sample is combined with two or more sensor RNAs that detect two or more target RNAs.

[0510] 158. A method of expressing a protein in a target cell, the method comprising combining the cell with the sensor RNA of any of the preceding items, wherein the target RNA is present in the target cell.

[0511] 159. The method according to item 158, further comprising combining the cell with an ADAR protein or a coding sequence thereof.

[0512] 160. The method according to item 158 or 159, wherein the ADAR protein is ADAR p150 .

[0513] 161. The method according to item 158, wherein the ADAR protein is a modified ADAR protein comprising an ADAR deaminase domain and an MS2 binding domain.

[0514] 162. The method according to any one of items 158 to 161, wherein the combining with a cell comprises contacting the cell with a lipid nanoparticle comprising the sensor RNA or an adeno-associated virus (AAV) comprising the sensor RNA, wherein the sensor RNA is contained in an AAV vector.

[0515] 163. The method according to any one of items 158 to 162, wherein said combining with a cell comprises transfecting said cell with a recombinant vector comprising said sensor RNA.

[0516] 164. The method according to any one of items 158 to 163, wherein the target RNA is associated with a disease or condition.

[0517] 165. The method according to any one of items 158 to 164, wherein said exporter treats said disease or condition.

[0518] 166. The method according to any one of items 158 to 165, wherein the target RNA is encoded by a gene fusion, a splice variant or a gene variant comprising a single nucleotide polymorphism.

[0519] 167. The method according to item 166, wherein said recombinant vector is selected from the group consisting of a plasmid, a viral vector, a cosmid and an artificial chromosome.

[0520] 168. A recombinant vector comprising the sensor RNA of any of the preceding items.

[0521] 169. The recombinant vector according to item 168, wherein said recombinant vector is selected from the group consisting of a plasmid, a viral vector, a cosmid and an artificial chromosome.

[0522] 170. A kit comprising the sensor RNA of any of the preceding items.

[0523] 171. The kit according to item 170, further comprising an ADAR protein or a coding sequence thereof.

[0524] 172. The kit according to item 171, wherein the ADAR protein is ADAR p150 .

[0525] 173. The kit according to item 171, wherein the ADAR protein is a modified ADAR protein comprising an ADAR deaminase domain and an MS2 binding domain.

[0526] 174. The kit according to any one of items 170 to 173, further comprising a biological sample with the target RNA and a biological sample without the target RNA.

[0527] 175. The kit according to any one of items 1 to 36, wherein the combining comprises administering to a patient.

[0528] 176. The method according to any one of items 37-72, wherein the combination comprises administering the sensor RNA to a patient.

[0529] 177. The method according to any of items 73-107, wherein the combination comprises administering the sensor RNA to a patient.

[0530] 178. The method according to any of items 107-132, wherein the combination comprises administering the sensor RNA to a patient.

[0531] 179. The method according to any of items 133-167, wherein the combination comprises administering the sensor RNA to a patient.

[0532] In at least some previously described embodiments, one or more elements used in one embodiment may be used interchangeably in another embodiment, unless such replacement is technically infeasible. It will be appreciated by those skilled in the art that various other omissions, additions and modifications may be made to the above methods and structures without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the subject matter defined by the appended claims.

[0533] Those skilled in the art will appreciate that, in general, the terms used herein, and particularly in the appended claims (e.g., the bodies of the appended claims), are generally intended to be "open" terms (e.g., the term "including" should be interpreted as "including but not limited to", the term "having" should be interpreted as "having at least", the term "comprising" should be interpreted as "including but not limited to", etc.). Those skilled in the art will also appreciate that if a specific number of introduced claim recitations is intended, such an intent will be explicitly recited in the claim, and in the absence of such a recitation, such an intent is not present. For example, to aid understanding, the following appended claims may contain the use of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of such phrases should not be interpreted as implying that the introduction of a claim recitation by the indefinite article "a" or "an" limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and an indefinite article such as "a" or "an" (e.g., "a" and / or "an" should be interpreted as meaning "at least one" or "one or more"); the same applies to the use of definite articles to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, one skilled in the art will recognize that such recitation should be interpreted as indicating at least the number recited (e.g., the mere recitation "two recitations" without other modifiers means at least two recitations, or two or more recitations). In addition, in those cases where a convention similar to "at least one of A, B, and C, etc." is used, generally, such construction is intended that one skilled in the art will understand the meaning of the convention (e.g., "a system having at least one of A, B, and C" will include, but is not limited to, systems including A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). In addition, in those cases where a convention similar to "at least one of A, B, or C, etc." is used, generally, such construction is intended that one skilled in the art will understand the meaning of the convention (e.g., "a system having at least one of A, B, or C" will include, but is not limited to, systems including A alone, B alone, C alone, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). Those skilled in the art will also understand that virtually any transitional word and / or phrase presenting two or more alternative terms, whether in the specification, claims or drawings, should be understood to include the possibility of one, either or both terms. For example, the phrase "A or B" will be understood to include the possibility of "A" or "B" or "A and B".

[0534] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0535] As will be understood by those skilled in the art, for any and all purposes, for example, in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily considered to be fully described and enables the same range to be decomposed into at least equal halves, one-third, one-quarter, one-fifth, one-tenth, etc. As a non-limiting example, each range discussed herein can be easily decomposed into a lower third, a middle third, and an upper third, etc. As will also be understood by those skilled in the art, all such as "until", "at least", "greater than", "less than" and similar languages ​​include the numbers listed and refer to the ranges that can be subsequently decomposed into sub-ranges as described above. Finally, as will be understood by those skilled in the art, the range includes each individual member. Therefore, for example, a group with 1-3 articles refers to a group with 1, 2 or 3 articles. Similarly, a group with 1-5 articles refers to a group with 1, 2, 3, 4 or 5 articles, and so on.

[0536] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent to one skilled in the art in light of the teachings of this invention that certain changes and modifications may be made without departing from the spirit or scope of the appended claims.

[0537] Therefore, the foregoing only illustrates the principles of the present invention.It should be understood that those skilled in the art will be able to think of various arrangements, although not explicitly described or shown herein, these arrangements embody the principles of the present invention and are included in its spirit and scope.In addition, all examples and conditional language recorded herein are mainly intended to help readers understand the principles of the present invention and the concepts contributed by the inventors to promote this area, and should be interpreted as not being limited to such specific examples and conditions of recording.In addition, all statements of the principles, aspects and embodiments of the present invention and their specific examples recorded herein are intended to cover their structural and functional equivalents.In addition, such equivalents are intended to include currently known equivalents and equivalents developed in the future, that is, no matter how the structure, any element of the developed performance of the same function.In addition, any content disclosed herein is not intended to be dedicated to the public, regardless of whether such disclosures are clearly recorded in the claims.

[0538] Therefore, the scope of the present invention is not intended to be limited to the exemplary embodiments shown and described herein. Instead, the scope and spirit of the present invention are embodied by the appended claims. In the claims, 35 U.S.C. § 112 (f) or 35 U.S.C. § 112 (6) is expressly defined as being cited for such a limitation in a claim only when the exact phrase "means for" or the exact phrase "step for" is recited at the beginning of a certain limitation in a claim; if such exact phrase is not used in the limitation in a claim, 35 U.S.C. § 112 (f) or 35 U.S.C. § 112 (6) is not cited.

Claims

1. A method for expressing a protein in a target cell, the method comprising: The target cells are combined with a sensor RNA comprising: (ia) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to a target RNA, wherein the sensor nucleotide sequence comprises a stem-loop sequence comprising one or more editable codons, and / or (ib) a first nucleotide sequence comprising a sensor nucleotide sequence that is reverse complementary to the 3'UTR of the target RNA, wherein the sensor nucleotide sequence comprises one or more editable codons, and (ii) a second nucleotide sequence encoding a first cleavage domain, and (iii) a third nucleotide sequence encoding an exported protein; wherein the target RNA is present in the target cell.

2. The method of claim 1, wherein the first nucleotide sequence comprises a sensor nucleotide sequence that is reverse complementary to a target RNA, wherein the sensor nucleotide sequence comprises a stem-loop sequence comprising one or more editable codons. 3 . The method of claim 1 , wherein the first nucleotide sequence comprises a sensor nucleotide sequence that is reverse complementary to a 3′UTR of a target RNA, wherein the sensor nucleotide sequence comprises one or more editable codons.

4. The method of any one of claims 1-3, wherein the editable codon is a stop codon, a start codon or an AUA codon.

5. The method of any one of claims 1-4, wherein the editable codon in (ia) comprises at least one base that mismatches with a sequence within the stem-loop relative to the one or more editable codons, and / or the editable codon in (ib) comprises at least one base that mismatches with the 3'UTR of the target RNA.

6. The method of any one of claims 1-5, wherein the cleavage domain is a 2A self-cleavage domain selected from the group consisting of T2A, P2A, E2A and F2A.

7. The method of any one of claims 1-6, wherein the exported protein is selected from the group consisting of a fluorescent protein, a genome modification protein, a transcription factor, a killer factor, a toxin, an antigen, a T cell receptor, a chimeric antigen receptor, a therapeutic protein, and an enzyme.

8. The method of any one of claims 1-7, wherein the target RNA is associated with a disease, condition, cell type, or tissue.

9. The method of any one of claims 1-8, wherein the target RNA is encoded by a gene fusion, a splice variant, or a gene variant comprising a single nucleotide polymorphism or a multiple nucleotide variant.

10. The method of any one of claims 1-9, wherein the exportin treats the disease or condition.

11. The method of any one of claims 1-10, wherein the stem-loop in (ia) is a GluR-B stem-loop or a modified variant thereof.

12. The method of any one of claims 1-11, wherein the sensor nucleotide sequence is reverse complementary to two or more discontinuous sequences within a single target RNA.

13. The method of any one of claims 1-12, wherein the combining with a target cell comprises contacting the target cell with a lipid nanoparticle comprising the sensor RNA.

14. The method of claims 1-13, wherein the combining with a target cell comprises contacting the target cell with an adeno-associated virus (AAV) comprising the sensor RNA, wherein the sensor RNA is contained in an AAV vector.

15. The method of any one of claims 1 to 14, wherein the sensor RNA further comprises a nucleotide sequence encoding a second sensor nucleotide sequence that is reverse complementary to a second target RNA, wherein the sequences of the first target RNA and the second target RNA are different.

16. The method of any one of claims 1 to 15, further comprising: (i) a fourth nucleotide sequence comprising a second cleavage domain, wherein the fourth nucleotide sequence is located before the first nucleotide sequence, and (ii) a fifth nucleotide sequence comprising a nucleotide sequence encoding a marker protein, wherein the fifth nucleotide sequence is located before the fourth nucleotide sequence.

17. The method of any one of claims 1 to 16, further comprising combining the target cell with an adenosine deaminase (ADAR) protein acting on RNA or a coding sequence thereof, wherein the ADAR protein is selected from the group consisting of ADAR2, ADAR p110 、ADAR p150 , a modified ADAR comprising an ADAR deaminase domain and an RNA motif binding domain.

18. The method of any one of claims 1-17, further comprising assaying for the presence of the exported protein, wherein the assaying comprises using microscopy, flow cytometry, immunoblotting, or a combination thereof.

19. The method of any one of claims 1-18, wherein combining comprises administering the sensor RNA to a patient.

Citation Information

Patent Citations

  • Polyurethane PSA for sensitive surfaces

    US20050027091A1

  • Chimeric T Cell Receptors, Nucleic Acids, And Methods Of Making And Using The Same

    US20220033459A1

  • Adeno-associated virus as eukaryotic expression vector

    US4797368A

  • AAV transduction vectors

    US5139941A

  • Methods for generating high titer helper-free preparations of released recombinant AAV vectors

    US6566118B1